NetDragon Announces Fourth Quarter and Fiscal Year 2014 Financial Results

Strong Revenue and Operational Metrics Growth

HONG KONG, March 26, 2015 /PRNewswire/ — NetDragon Websoft Inc. (“NetDragon” or “the Company”) (Hong Kong Stock Code: 0777), a leading developer and operator of online games and mobile internet platforms in China, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2014. A conference call and webcast is scheduled at 8 p.m. Hong Kong Time on March 26, 2015 to discuss the results and recent business developments.

Fiscal Year 2014 Financial Highlights

  • Revenue was RMB962.8 million, an increase of 8.9% from RMB 884.5 million last year.
  • Operating profit was RMB252.0 million, an increase of 24.3% from RMB202.8 million last year.
  • Profit from continuing operations attributable to owners of the Company was RMB176.7 million, an increase of 7.5% from RMB164.4 million last year.
  • Basic and diluted earnings per share were RMB34.77 cents and RMB34.22 cents, respectively.

Fourth quarter 2014 Financial Highlights

  • Revenue was RMB282.9 million, an increase of 21.6% quarter-over-quarter and 23.5% year-over-year.
  • Gross profit was RMB246.5 million, an increase of 17.9% quarter-over-quarter and 19.7% year-over-year.
  • Operating profit was RMB4.0 million, a decrease of 93.2% quarter-over-quarter and an increase from an operating loss of RMB1.7 million during the same period of 2013.
  • Non-GAAP operating profit[1] was RMB13.5 million, a decrease of 79.7% quarter-over-quarter and an increase of 19.4% year-over-year.
  • Loss attributable to owners of the Company was RMB19.4 million, compared to profit attributable to owners of the Company of RMB52.6 million during the previous quarter. Non-GAAP profit attributable to owners of the Company, which excludes several non-core operational items, was RMB6.8 million.
  • Basic and diluted losses per share were RMB3.78 cents and RMB3.82 cents, respectively.
  • The Board of Directors has proposed a final dividend of HK$0.20 per share subject to the approval by shareholders at the Annual General Meeting.

Fourth quarter 2014 Operational Highlights[2]

  • Peak concurrent users (“PCU”) for online games were 642,000.
  • Average concurrent users (“ACU”) for online games were 301,000.

“We experienced a healthy 8.9% increase in revenue to RMB962.8 million during the year as we further consolidated our market position in the gaming space and pushed forward with the development of our online education platform,” commented Mr. Dejian Liu, Chairman and Executive Director of NetDragon. “Our online games business continues to gain strong growth momentum during the quarter with peak concurrent users reaching 642,000 as revenues increased 6.7% year-over-year to RMB221.5 million. One of our newest games, Calibur of Spirit, continues to gain strong user traction following its selection for the World Cyber Arena last fall. We signed an exclusive China licensing agreement with Tencent and officially launched the game in January 2015 where it achieved record-high MAU of 7 million that month and monthly gross revenue over RMB21.0 million in February 2015. With such a strong performance at the beginning of its lifespan, we are confident that this game will develop into a substantial long-term new revenue stream as large scale marketing campaigns get underway and new updates are launched throughout the year. We launched new expansion packs for our flagship games during the period including an English version for Conquer Online which generated an 11-year high monthly revenue in December 2014. We are also excited to beta-launch Tiger Knight later this year.”

“We continued to incubate our mobile games business during the quarter and have seen encouraging progress from Eudemons Online Pocket Version which was officially launched in January 2015 and is expected to register over RMB10 million in monthly gross revenue in March 2015. The iOS and Android versions of Blade & Sword continue to make steady progress through the various stages of development while the Arabic version of The Pirate remains extremely popular across the Middle East and North Africa where it is expected to continue to grow as new updates are launched.” 

“NetDragon’s new strategic business focus continues to be its online education business which completed a round of series A preference shares funding of US$52.5 million in February 2015. The participation of globally renowned investors demonstrates the confidence they have in our unique position to leverage our proven world-class mobile internet and gaming expertise, large-scale technology resources and team infrastructure to build an online and mobile education ecosystem. We are making very solid progress in the design and development of our educational products, and remain on track to gradually roll them out as each development milestone is achieved. We expect to make exciting announcements in the coming months regarding our overall product strategy and the unique value proposition we can create for students, educators and parents.” 

Mr. Ben Yam, Chief Financial Officer, added, Non-GAAP profit for the quarter was RMB4.1 million which is a blended figure combining our highly profitable gaming business and our online education business which is currently in product development stage. During the quarter, our online games business achieved revenue growth of 6.7% year-over-year and 9.8% sequentially with a stable operating cost structure. We also continue to invest heavily in the development of educational products which requires significant investments in staff costs and has reduced the blended profitability in the short-term. These investments however, are the best use of our cash and demonstrate our commitment to building an online education business that will become another cornerstone for our long-term success.”

[1] See the ‘Non-GAAP Financial Measures’ section at the bottom of this release for more details

[2] PCU and ACU include the Company’s new micro-client game Calibur of Spirit

Fourth quarter 2014 Unaudited Financial Results

Revenue

Revenue was RMB282.9 million, an increase of 21.6% from RMB232.7 million in the previous quarter and 23.5% from RMB229.0 million during the same quarter last year.

Revenue from online games and other business generated from China was RMB229.0 million, an increase of 16.9% from RMB195.9 million in the previous quarter and 11.6% from RMB205.2 million in the same quarter last year. The increase in revenue was mainly due to the strong performance of Eudemons Online and Calibur of Spirit.

Revenue from online games and other business generated from overseas markets was RMB53.9 million, an increase of 46.2% from RMB36.8 million in the previous quarter and 126.0% from RMB23.8 million in the same quarter last year due to the growth in the Company’s mobile solutions and marketing business operated by its Hong Kong-based subsidiary Cherrypicks.

Gross profit and gross margin

Gross profit was RMB246.5 million, an increase of 17.9% from RMB209.2 million in the previous quarter and 19.7% from RMB205.9 million in the same quarter last year. Gross margin was 87.2%, compared with 89.9% in the previous quarter and 89.9% in the same quarter last year. The decreases in gross margin were partly due to the inclusion of Cherrypicks which generates lower gross margins when compared with NetDragon’s online games business.

Operating expenses

Selling and marketing expenses were RMB51.2 million, representing an increase of 32.8% from RMB38.6 million in the previous quarter, and 61.6% from RMB31.7 million during the same period last year. The increase in selling and marketing expenses was mainly due to the increase in advertising and promotional expenses of Eudemons Online and Calibur of Spirit.

Administrative expenses were RMB120.9 million, representing an increase of 55.9% from RMB77.5 million during the third quarter of 2014 and a decrease of 14.2% from RMB140.9 million during the same period last year. The quarter-over-quarter increase in administrative expenses was mainly due to the increase in (i) staff costs; and (ii) depreciation and amortization. The year-over-year decrease in administrative expenses was mainly due to the (i) decrease in exchange loss on foreign currencies; and (ii) expenditure of domain name during the same period last year.

Development costs were RMB89.3 million, representing an increase of 32.6% from RMB67.3 million during the third quarter of 2014 and an increase of 100.8% from RMB44.5 million during the same period last year. The sequential and year-over-year increases in development costs was mainly due to increases in (i) staff costs; and (ii) outsourcing fees.

Other expenses were RMB12.0 million, representing an increase of 226.7% from RMB3.7 million during the third quarter of 2014 and 126.4% from RMB5.3 million during the same period last year. The sequential and year-over-year increases in other expenses was mainly due to the increase in allowances on trade receivables.

Operating profit

Operating profit from continuing operations was RMB4.0 million, a decrease of 93.2% from RMB57.7 million in the third quarter of 2014, and an increase from an operating loss of RMB1.7 million in the same quarter last year.

Taxation

Taxation was RMB9.4 million, an increase of 126.6% from RMB4.2 million during the third quarter of 2014 and a decrease of 43.7% from RMB16.8 million during the same quarter last year. The sequential increase in taxation was mainly due to an under provision for tax in 2014 while the year-over-year decrease was mainly due to the decrease in taxable profit.

(Loss) profit for the period from continuing operations

Loss from continuing operations was RMB22.2 million, compared with profit of RMB52.4 million in the previous quarter and loss of RMB2.7 million in the same quarter last year.

Non-GAAP profit from continuing operations, which excludes a net loss on held-for-trading investments (which tend to fluctuate quarter-to-quarter), an exchange loss and amortization of intangible assets resulting from the acquisition of Cherrypicks last year, was RMB4.1 million during the fourth quarter of 2014. 

Liquidity

As of December 31, 2014, NetDragon had bank deposits, bank balances, cash, pledged bank deposits and held-for trading liquid investments of approximately RMB3,484.8 million, compared with RMB4,483.7 million as of December 31, 2013. 

Business Review and Outlook

Games

On October 26th, 2014, NetDragon began beta testing “Goddess Era,” a new expansion pack for Eudemons Online that introduces the “Goddess Gifts” system and allows players to enhance their character’s attributes free of charge. The new expansion pack, which enhances gameplay and increases user stickiness, is expected to begin closed beta testing during the first half of 2015. Eudemons Online celebrated its anniversary in March 2015 with in-game activities. Conquer Online, the Company’s other flagship title, also launched a new expansion pack “King of Kungfu” in October 2014. By adding new classes to the game, the expansion pack provides more excitement for players. The English, French, Spanish and Arabic versions of Conquer Online’s expansion pack were also launched overseas. A class-updated version of Conquer Online — The Rhapsody of Ice and Fire: Taoist Ascending will be launched during the first half of 2015 and is expected to maintain the game’s market share overseas. Revenue generated by the English version of Conquer Online in December 2014 reached an 11-year high as a result of the enhanced competitiveness of the game in various countries and regions worldwide.

Calibur of Spirit, NetDragon’s first MOBA web micro-client game, officially began open-beta testing on January 16, 2015, achieving MAU of 7 million that month and over RMB21.0 million in monthly gross revenue in February 2015 demonstrating the Company’s world-class game-design and development capabilities. The game was previously selected for the 2014 World Cyber Arena held in Yinchuan, China in October 2014. Marketing and promotional events have rapidly increased the game’s operational metrics. The Company also signed an exclusive China licensing agreement for Calibur of Spirit with Tencent at the end of 2014. NetDragon is confident that revenue from this game will grow substantially as large scale publicity campaigns get underway. The Portuguese and Spanish versions of Calibur of Spirit have already been completed and are scheduled to begin testing in Latin America and Europe in the first half of 2015. The Company’s in-house developed 3D action war game Tiger Knight began its first round of internal beta testing during the fourth quarter of 2014 and will begin its second round during the second quarter of 2015. A new expansion pack for Way of the Five was launched during the quarter along with annual celebration activities which began on March 7, 2015.

NetDragon continued to release content updates for its mobile game including one for the Arabic version of The Pirate in the fourth quarter of 2014 in an effort to solidify its existing player base as well as to seek out new players. This resulted in new record high monthly gross revenue in October 2014. The Company is committed to its strategy of developing high-quality products and continues to develop mobile products to ensure their success in an increasingly competitive market. The iOS version of Blade & Sword, NetDragon’s self-developed mobile 2.5D martial arts role-play game, finished closed beta testing in November 2014 and is currently undergoing closed beta testing of its iOS version with the Android version expected to begin closed beta testing in the first quarter of 2015. Martial Overlord, a mobile 3D martial arts action game, began channel testing in November 2014 and its second round of beta-testing in March 2015. The iOS version of Eudemons Online Pocket Version was officially launched on Apple’s AppStore in January 2015 with open beta testing for the Android version beginning at the same time. Waku & Maou, is a real-time strategy-based collectible mobile card game which began being operated by China’s leading mobile game publisher in January 2015. The Android version began its first round of closed beta testing in January 2015 with open beta testing for the Android and iOS version expected to begin during the first half of 2015.

Online and Mobile Education 

The Company made very strong progress in research and development, pedagogy integration, content partnership and acquisition, sales channel build-out and M&A discussions for its online and mobile education business during the fourth quarter and fiscal year 2014.

Research & Development — The Company’s educational product design and R&D team currently comprises of over 350 staff. With world-class leadership, the team focuses on the design and development of both software and hardware, and over the course of 2014, has achieved many milestones in the development of high-quality and differentiated software. The Company’s 101 student tablet, which has also gone through multiple design iterations, will be commercially launched during the third quarter of 2015. The Company’s product development roadmap to create a holistic, integrated total-solution for online and mobile education remains unchanged. The initial version of the commercialized product will be focused on enabling best-in-class interconnectivity in the classroom, and will create true value through a transformational yet easy-to-learn educational solution for teachers and students. The Company will update the market when more information on product launches is available. In addition, the Company expects to officially open a research lab in Beijing in the coming months to extend its talent acquisition reach. The current plan is to scale the office to hundreds of R&D staff within one to two years to accelerate educational research and development.

Pedagogy Integration — NetDragon continues to deepen its partnership with Beijing Normal University, China’s top education university, to ensure the most effective pedagogy is being developed and integrated based on collaboration with proven hands-on educators. In November 2014 NetDragon, signed an agreement with Beijing Normal University to jointly research e-classroom design in an effort to develop insight into how software and hardware can best be integrated with various teaching models in a classroom learning environment. One March 18, 2015, NetDragon’s education subsidiary and Beijing Normal University also announced the establishment of Smart Learning Institute which will provide a unique platform to integrate the most advanced e-pedagogy with NetDragon’s mobile internet expertise and technological know-how. The Company believes the accumulation and understanding of pedagogy through its partnerships with top-tier universities and institutions including Beijing Normal University will form a significant barrier to entry.

Content Partnerships — NetDragon signed a MOU in November 2014 with a subsidiary of Pearson, the globally renowned leading education company, and Beijing Normal University, to develop a smart education solution. This collaboration will leverage Pearson’s rich K12 educational content resources to build China’s leading integrated smart education solution. In addition, the Company is also in discussions with numerous major publishers and content partners to enrich the content on its platform.

Channel Build-Out — The Company is in the process of building a nationwide school distribution network for its educational products. Currently, the Company is in discussion with over 20 regional and local distributors and has secured distribution agreements with a number of them. The Company is also in active discussions with several channel partners in addition to conventional distributors.  

M&A — NetDragon is in advanced discussions with multiple major acquisition targets in the online education space. If such acquisitions materialize, the Company’s competitive position in the market will further be enhanced.

Fundraising — In February 2015, NetDragon’s education subsidiary closed a Series A equity fundraising round of US$52.5 million led by IDG, Vertex (a Temasek subsidiary) and Alpha Animation, at a valuation of US$477.5 million

Other developments Netdragon was officially admitted to the Education Informatization Standard Committee under the Ministry of Education in November 2014. Membership will allow NetDragon to participate in the forming of technology standards, which will be conducive in developing the right products that meet or exceed regulatory standards. NetDragon is one of a very select few tier-one mobile internet companies who are members of the committee.

Non-GAAP Financial Measures

To supplement the consolidated results of the Company prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”), the use of certain non-GAAP measures is provided solely to enhance the overall understanding of the Group’s current financial performance. These non-GAAP measures are not expressly permitted measures under HKFRSs and may not be comparable to similarly titled measures for other companies. The non-GAAP financial measures of the Group exclude share-based payments expense, amortisation of intangible assets arising from acquisition of subsidiaries, interest income on pledged bank deposits, exchange gain (loss) on pledged bank deposits, secured bank borrowings and redeemable convertible preferred shares, net gain (loss) on derivative financial instruments, finance costs and gain on disposal of subsidiaries (net of related income tax).

Management Conference Call

NetDragon will host a management conference call and webcast to review its the fourth quarter and fiscal year 2014 results on Thursday, March 26, 2015, at 8pm Hong Kong time.

Details of the live conference call are as follows:

International Toll                              

65-6723-9381

US Toll Free                                       

1-866-519-4004

Hong Kong Toll Free                          

800-906-601

China Toll Free (for fixed line users)      

800-819-0121

China Toll Free (for mobile users)         

400-620-8038

Passcode                                           

NetDragon

A live and archived webcast of the conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.netdragon.com/investor/ir_events.shtml. Participants in the live webcast should visit the aforementioned website 10 minutes prior to the call, then click on the icon for “4Q and Fiscal Year 2014 Results Conference Call” and follow the registration instructions.

About NetDragon

NetDragon Websoft Inc. (HKSE: 0777) is a leading innovator and creative force in China’s online games and mobile internet industries. Established in 1999, NetDragon is leading developer in the mobile internet segment with a highly successful track record which includes the development of flagship MMORPGs such as Eudemons Online and Conquer Online, China’s number one online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless, which was sold to Baidu in what was at the time the largest internet M&A transaction in China in 2013. Being a China’s pioneer in overseas expansion, NetDragon directly operates a number of game titles in over 10 languages internationally since 2003. NetDragon continues to strive for developing mobile games and software applications for users. In recent years, NetDragon has also become a major player in China’s online and mobile education industry as it works to leverage its mobile internet technologies expertise and know-how to develop a game-changing education ecosystem product.

For investor enquiries, please contact:

NetDragon Websoft Inc.

Ms. Maggie Zhou
Senior Director of Investor Relations
Tel.: +852 2850 7266; +86 591 8754 3120
Email: maggie@nd.com.cn; ndir@nd.com.cn
Website: www.nd.com.cn/ir

 

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

(FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED 31 DECEMBER 2014)

 

4Q 2014

3Q 2014

2014

2013

(Unaudited)

(Unaudited)

(Audited)

(Audited)

RMB ‘000

RMB ‘000

RMB ‘000

RMB ‘000

Continuing operations

Revenue

282,880

232,702

962,817

884,518

Cost of revenue

(36,342)

(23,530)

(102,844)

(81,426)

Gross profit

246,538

209,172

859,973

803,092

Other income and gains

32,464

36,034

157,101

44,980

Selling and marketing expenses

(51,206)

(38,569)

(152,495)

(106,200)

Administrative expenses

(120,876)

(77,538)

(326,934)

(366,143)

Development costs

(89,278)

(67,341)

(249,260)

(162,857)

Other expenses

(11,977)

(3,666)

(34,027)

(10,046)

Share of losses of associates

(1,715)

(406)

(2,354)

(16)

Operating profit 

3,950

57,686

252,004

202,810

Interest income on pledged bank deposits

475

638

2,794

4,883

Exchange gain (loss) on pledged bank deposits and secured bank borrowings

1,188

(5,081)

4,593

Net (loss) gain on derivative financial instrument

(646)

6,817

(5,481)

Gain on disposal of available-for-sale investment

5,761

Net (loss) gain on held-for-trading investments

(16,905)

(1,553)

(17,304)

8,756

Finance costs

(235)

(728)

(3,212)

(4,651)

(Loss) profit before taxation

(12,715)

56,585

236,018

216,671

Taxation

(9,442)

(4,166)

(64,197)

(50,264)

(Loss) profit for the period/year from continuing operations

(22,157)

52,419

171,821

166,407

Discontinued operations

Profit for the period/year from discontinued operations

6,056,041

(Loss) profit for the period/year

(22,157)

52,419

171,821

6,222,448

Other comprehensive expense for the period/year, net of income tax:

Exchange differences arising on translation of foreign operations that may be reclassified subsequently to profit or loss

(461)

(161)

(40)

(1,130)

Total comprehensive (expense) income for the period/year

(22,618)

52,258

171,781

6,221,318

(Loss) profit for the period/year attributable to:

 -Owners of the Company

(19,406)

52,595

176,681

6,140,776

 -Non-controlling interests

(2,751)

(176)

(4,860)

81,672

(22,157)

52,419

171,821

6,222,448

(Loss) profit for the period/year attributable to owner of the Company:

 -from continuing operations

(19,406)

52,595

176,681

164,352

 -from discontinued operations

5,976,424

(Loss) profit for the period/year attributable to owner of the Company

(19,406)

 

52,595

176,681

 

6,140,776

(Loss) profit for the period/year attributable to non-controlling interests:

 -from continuing operations

(2,751)

(176)

(4,860)

2,055

 -from discontinued operations

79,617

(Loss) profit for the period/year attributable to non-controlling interests

(2,751)

(176)

(4,860)

81,672

Total comprehensive (expense) income attributable to:

-Owners of the Company

(19,867)

52,434

176,641

6,139,646

-Non-controlling interests

(2,751)

(176)

(4,860)

81,672

(22,618)

52,258

171,781

6,221,318

RMB cents

RMB cents

RMB cents

RMB cents

(Loss) earnings per share

From continuing and discontinued operations

– Basic

(3.78)

10.31

34.77

1,213.44

– Diluted

(3.82)

10.27

34.22

1,181.10

From continuing operations

– Basic

(3.78)

10.31

34.77

32.48

– Diluted

(3.82)

10.27

34.22

31.75

 

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (AS AT 31 DECEMBER 2014)

2014

2013

(Audited)

(Audited)

RMB’000

RMB’000

Non-current assets

Property, plant and equipment

822,704

532,684

Prepaid lease payments

 

378,673

185,819

Investment property

15,725

Intangible assets

141,254

Interests in associates

28,795

1,299

Available-for-sale investments

5,000

5,000

Loan receivables

18,327

16,041

Deposits made for acquisition of property, plant and equipment

35,967

16,769

Other receivable

60,969

Goodwill

40,013

12,534

Deferred tax assets

54

54

1,470,787

846,894

Current assets

Prepaid lease payments

2,708

2,583

Loan receivables

1,578

713

Trade receivables

51,072

41,718

Amounts due from customers for contract work

7,252

Other receivables, prepayments and deposits

210,098

69,770

Amounts due from related companies

1,704

4,564

Amounts due from associates

367

Held-for-trading investments

211,584

20,735

Pledged bank deposit

236,805

107,368

Bank deposits

1,999,644

3,051,289

Bank balances and cash

1,036,788

1,304,355

3,759,600

4,603,095

Current liabilities

Trade and other payables

209,214

152,837

Amounts due to customers for contract work

424

Deferred income

25,595

26,553

Amount due to a related company

1,891

Amount due to an associate

8

Secured bank borrowing

236,805

104,672

Other financial liability

3,122

Income tax payable

137,648

539,927

611,585

827,111

Net current assets

3,148,015

3,775,984

Total assets less current liabilities

4,618,802

4,622,878

Non-current liabilities

Other payables

1,283

Deferred tax liabilities

116

1,399

Net assets

4,617,403

4,622,878

Capital and reserves

Share capital

36,943

37,664

Share premium and reserves

4,529,971

4,577,478

Equity attributable to owners of the Company

4,566,914

4,615,142

Non-controlling interests

50,489

7,736

4,617,403

4,622,878

 

NetDragon Websoft Inc. to Report Fourth Quarter and Fiscal Year 2014 Financial Results on March 26, 2015

HONG KONG, March 11, 2015 /PRNewswire/ — NetDragon Websoft Inc. (“NetDragon”; Stock Code: 777), a leading developer and operator of online games and mobile internet platforms in China, today announced that it will report its financial results for the fourth quarter and fiscal year 2014 on Thursday, March 26, 2015, after the close of Hong Kong stock market. Following release of the results announcement, NetDragon’s management will host a conference call and webcast to discuss the results at 8:00 PM on March 26, 2015 Hong Kong Time.                                                                                        

Details of the live conference call are as follows:

Time: 8:00 PM Beijing / Hong Kong Time / 8:00 AM Eastern Standard Time, March 26, 2015 

International Toll 

65-6723-9381

US Toll Free

1-866-519-4004

Hong Kong Toll Free

800-906-601

China Toll Free (for fixed line users)

800-819-0121

China Toll Free (for mobile users)

400-620-8038

Passcode

NetDragon

A live and archived webcast of the conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.netdragon.com/investor/ir_events.shtml. Participants in the live webcast should visit the aforementioned website 10 minutes prior to the call, then click on the icon for “4Q and Fiscal Year 2014 Results Conference Call” and follow the registration instructions.

About NetDragon

NetDragon Websoft Inc. (HKSE: 0777) is a leading innovator and creative force in China’s online games and mobile internet industries. Established in 1999, NetDragon is leading developer in the mobile internet segment with a highly successful track record which includes the development of flagship MMORPGs such as Eudemons Online and Conquer Online, China’s number one online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless, which was sold to Baidu in what was at the time the largest internet M&A transaction in China in 2013. Being a China’s pioneer in overseas expansion, NetDragon directly operates a number of game titles in over 10 languages internationally since 2003. NetDragon continues to strive for developing mobile games and software applications for users. In recent years, NetDragon has also become a major player in China’s online and mobile education industry as it works to leverage its mobile internet technologies expertise and know-how to develop a game-changing education ecosystem product.

For investor enquiries, please contact:

NetDragon Websoft Inc.
Ms. Maggie Zhou
Senior Director of Investor Relations
Tel.:     +852 2850 7266 / +86 591 8754 3120
Email:   maggie@nd.com.cn; ndir@nd.com.cn
Website: www.nd.com.cn/ir

China Cord Blood Corporation to Report Third Quarter and First Nine Months of Fiscal 2015 Financial Results

Earnings Call Scheduled for 8:00 a.m. ET on February 26, 2015

HONG KONG, Feb. 17, 2015 /PRNewswire/ — China Cord Blood Corporation (NYSE: CO) (the “Company”) today announced its plan to release its unaudited financial results for the third quarter and first nine months of fiscal 2015 on Wednesday, February 25, 2015, after market close in the US.

The Company will host a conference call at 8:00 a.m. ET on Thursday, February 26, 2015 to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company’s IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL above. Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 3388198.

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the third quarter and first nine months of fiscal 2015 earnings press release will be available at http://www.chinacordbloodcorp.com, in the Investor Center/Press Release section, after 4:00 p.m. ET on Wednesday, February 25 , 2015 and in the Company’s report on Form 6-K for the month of February, 2015, available on the Securities and Exchange Commission’s website at www.sec.gov.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company’s website at http://www.chinacordbloodcorp.com.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: william.zima@icrinc.com

AMRI Announces Fourth Quarter and Full Year 2014 Results

— Fourth quarter contract revenue of $80.7 million, up 35% from 2013

— Full year 2014 contract revenue of $250.7 million, up 19% from 2013

— Fourth quarter adjusted diluted EPS of $0.28 up 33% from $0.21 in 2013, including a $0.03 decrease in EPS from royalties in the current quarter

— Full year adjusted diluted EPS of $0.63 compared to $0.68 in 2013, including a $0.21 decrease in EPS from royalties in the current year

— Full year 2015 contract revenue expected to be between $335 and $370 million, up 40% at the midpoint.

ALBANY, N.Y., Feb. 12, 2015 /PRNewswire/ — AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2014.

“While our OsoBio facility resumed full operations later than anticipated, after we learned in the fall of 2014 that a remediation would be necessary, strong execution led us to finish 2014 with record performances in each of our businesses, as reflected by a greater than 30% increase in quarterly revenue and adjusted earnings,” said William S. Marth, AMRI’s president and chief executive officer.

“During 2014, we reorganized our discovery business, optimizing our resource mix and laying the ground work for a differentiated discovery platform. We advanced our growth in generics, initiating multiple development programs across all segments of our business, and we completed and integrated two acquisitions and announced a third, expanding our capabilities into very attractive, high demand areas such as controlled substances, sterile manufacturing and product development. Lastly, we created sustainable shareholder value, replacing declining royalties with an expanding, profitable contract business.

“We have much to be proud of in 2014 and are poised for a strong 2015. Despite a significant headwind from the loss of Allegra royalties in 2015, we believe continued strong growth in our base business, the contribution of our acquisitions, together with enhanced operational discipline, will lead to continued, significant growth in revenue and earnings in 2015.”

Fourth Quarter 2014 Results 

Total revenue for the fourth quarter of 2014 was $86.6 million, an increase of 29% compared to total revenue of $67.1 million reported in the fourth quarter of 2013.

Total contract revenue for the fourth quarter of 2014 was $80.7 million, an increase of 35% compared to contract revenue of $59.7 million reported in the fourth quarter of 2013. Adjusted contract margins were 23% for the fourth quarter of 2014, compared with 21% for the fourth quarter of 2013, driven by the growth of the Drug Product business, increased capacity utilization, and the benefit of cost reduction initiatives and facility optimization. Adjusted contract margins exclude the following items that are included under U.S. GAAP: business interruption costs, purchase accounting depreciation and amortization and business acquisition costs. For a reconciliation of U.S. GAAP contract margins as reported to adjusted contract margins for the 2014 and 2013 reporting periods, please see Table 1 at the end of press release.

Royalty revenue in the fourth quarter of 2014 was $5.9 million, a decrease of 21% from $7.4 million in the fourth quarter of 2013. Royalty revenue for the fourth quarter of 2014 includes $3.4 million in royalties from the Allegra® products as well as $2.5 million from the net sales of certain amphetamine salts sold by Actavis.

Net loss under U.S. GAAP was $(1.9) million, or $(0.06) per diluted share, in the fourth quarter of 2014, compared to U.S. GAAP net income of $4.3 million, or $0.13 per diluted share for the fourth quarter of 2013. Net income on an adjusted basis in the fourth quarter of 2014 was $9.2 million, or $0.28 per diluted share, compared to adjusted net income of $6.8 million or $0.21 per diluted share in 2013. Net income on an adjusted basis excludes the following items that are included under U.S. GAAP: business interruption charges, restructuring and impairment charges, convertible debt interest and amortization charges, business acquisition costs, executive transition costs, postretirement benefit plan settlement gains, write-offs of deferred financing costs, non-recurring income tax adjustments, litigation settlements, insurance demutualization gains, losses on disposals of fixed assets related to restructuring activities, ERP implementation costs, and depreciation and amortization of purchase accounting adjustments. For a reconciliation of U.S. GAAP net income (loss) and earnings (loss) per diluted share as reported to adjusted net income and earnings per diluted share for the 2014 and 2013 reporting periods, please see Table 2 at the end of this press release.

Full Year 2014 Results

Total revenue for the year ended December 31, 2014 was a record $276.6 million, an increase of 12% compared to total revenue of $246.6 million for the same period in 2013.

Total contract revenue for the full year 2014 was a record $250.7 million, an increase of 19% compared to contract revenue of $210.0 million for 2013. Adjusted contract margins were 19% for the full year 2014, compared to 18% in 2013.

Royalty revenue for the full year 2014 was $25.9 million, a decrease of 29% from $36.6 million in 2013, in line with expectations. Royalty revenue for the full year 2014 includes $16.3 million in royalties from the Allegra® products, as well as $9.6 million from the net sales of certain amphetamine salts sold by Actavis.

Net loss under U.S. GAAP for the full year 2014 was $(3.3) million, or $(0.10) per diluted share, compared to U.S. GAAP net income of $11.8 million, or $0.37 per diluted share for the full year 2013. Net income on an adjusted basis in the full year 2014 was $20.7 million or $0.63 per diluted share, compared to adjusted net income of $21.5 million or $0.68 per diluted share in 2013. Adjusted net income in 2014 includes a $6.4 million decline in royalty income and $0.7 million of income from operations acquired during 2014.

For a reconciliation of U.S. GAAP net income (loss) and earnings (loss) per diluted share as reported to adjusted net income and earnings per diluted share for the 2014 and 2013 reporting periods, please see Table 2 at the end of this press release. Financial results for the three months and year ended December 31, 2013 have been updated from previously reported amounts to reflect prior period income tax adjustments identified during the second quarter of 2014. The Company considers the adjustments to be immaterial to the impacted periods.

Segment Results

Drug Discovery Services (DDS) 

Three Months Ended

Year Ended

December 31,

December 31,

(Unaudited; $ in thousands)

2014

2013

2014

2013

DDS Contract Revenue

$    19,741

$    18,404

$      76,737

$      77,418

Cost of Contract Revenue

15,482

16,028

62,401

66,604

Contract Gross Profit

4,259

2,376

14,336

10,814

Contract Gross Margin

22%

13%

19%

14%

Discovery and Development Services (DDS) contract revenue for the fourth quarter of 2014 increased 7% to $19.7 million, compared to $18.4 million the fourth quarter of 2013, primarily due to an increase in development services revenue. DDS gross margins increased to 22% from 13% in the fourth quarter of 2013, driven by the benefit of cost reduction initiatives and facility optimization.

For the full year 2014, DDS contract revenue decreased to $76.7 million from $77.4 million in 2013. A decline in discovery service revenue was offset by an increase in development service revenue. DDS gross margins increased to 19% in 2014 from 14% in 2013, driven by the benefit of cost reduction initiatives and facility optimization.

Active Pharmaceutical Ingredients (API)

Three Months Ended

Year Ended

December 31,

December 31,

(Unaudited; $ in thousands)

2014

2013

2014

2013

API Contract Revenue

$    46,204

$    38,301

$  144,349

$  125,871

Cost of Contract Revenue

34,200

27,975

111,873

95,144

Contract Gross Profit

12,004

10,326

32,476

30,727

Contract Gross Margin

26%

27%

22%

24%

Adjusted Contract Gross Profit (1)

12,220

10,326

32,882

30,727

Adjusted Contract Gross Margin (1)

26%

27%

23%

24%

(1) Refer to Table 1 included in this release for the reconciliation of U.S. GAAP contract gross profit and contract gross margin to adjusted contract gross profit and adjusted contract gross margin as a percentage of contract revenue.

API contract revenue for the fourth quarter of 2014 increased 21% compared to the same period of 2013 due primarily an increase in API shipments to customers, and the addition of Cedarburg Pharmaceuticals. Excluding the Cedarburg acquisition, contract revenue increased 14% compared to the fourth quarter 2013. API adjusted contract margins for the fourth quarter of 2014 decreased to 26% from 27% in the fourth quarter of 2013, due to the mix of business within the segment.

For the full year 2014, API contract revenue increased 15% to $144.3 million from $125.9 million in 2013, due primarily to the addition of Cedarburg Pharmaceuticals. Excluding the acquisition of Cedarburg, API contract revenue increased 7% compared to the full year 2013. API adjusted gross margins decreased to 23% in 2014 from 24% in 2013, due to the mix of business within the segment.

Drug Product Manufacturing (DPM)

Three Months Ended

Year Ended

December 31,

December 31,

(Unaudited; $ in thousands)

2014

2013

2014

2013

DPM Contract Revenue

$    14,767

$      3,010

$    29,619

$      6,712

Cost of Contract Revenue

16,449

3,100

34,919

10,175

Contract Gross Loss

(1,682)

(90)

(5,300)

(3,463)

Contract Gross Margin

-11%

-3%

-18%

-52%

Adjusted Contract Gross Profit (Loss) (1)

1,761

(90)

1,467

(3,463)

Adjusted Contract Gross Margin (1)

12%

-3%

5%

-52%

(1) Refer to Table 1 included in this release for the reconciliation of U.S. GAAP contract gross loss and contract gross margin to adjusted contract gross profit (loss) and adjusted contract gross margin as a percentage of contract revenue.

Drug Product Manufacturing contract revenue for the fourth quarter of 2014 increased $11.8 million over the same period of 2013 and includes $10.3 million of revenue from Oso Biopharmaceuticals Manufacturing (OsoBio) that was acquired in July 2014. Drug Product adjusted contract margins for the fourth quarter of 2014 increased to 12% compared to -3% the same period of 2013, driven by volume increases, improved mix and the addition of the OsoBio business, however contract margins were significantly impacted at the Company’s Albuquerque facility as a result of the previously disclosed business interruption event.

For the full year 2014, Drug Product contract revenue increased $22.9 million to $29.6 million from $6.7 million in 2013, due primarily to the addition of $16.7 million in revenue from OsoBio and a 92% increase in revenue from the company’s Burlington operations. Drug Product adjusted gross margins improved to 5% in 2014 from -52% in 2013, due to the addition of OsoBio and increased capacity utilization at our Burlington facility.

Liquidity and Capital Resources

In the fourth quarter 2014, AMRI expanded its existing revolving line of credit from $50 million to $75 million with the addition of another bank to the facility.

At December 31, 2014, AMRI had cash, cash equivalents and restricted cash of $51.0 million, compared to $23.9 million at September 30, 2014. The increase in cash and cash equivalents for the quarter ended December 31, 2014 was primarily due to $35 million in proceeds from the Company’s line of credit, partially offset by cash used in operations of $2.0 million and $5.2 million of capital expenditures. Total common shares outstanding, net of treasury shares, were 32,627,940 at December 31, 2014.

In January 2015, AMRI acquired a Glasgow, UK-based drug product formulation business for $24 million and expects to complete the previously announced acquisition of SSCI/ West Lafayette, Ind. in February 2015.

Financial Outlook

AMRI estimates the following for full year 2015:

  • Full year contract revenue is expected to be between $335 and $370 million, an increase of 40% at the midpoint, including
    • DDS revenue of approximately $98 million
    • API revenue of approximately $162 million
    • Drug Product revenue of approximately $92 million
  • Royalty revenue of between $13 and $14 million, including approximately $4 million of Allegra royalties, which expire fully in the third quarter 2015
  • Adjusted selling, general and administrative expenses at approximately 17% of contract revenue
  • Adjusted EBITDA between $59 and $65 million, up 34% at the midpoint
  • Adjusted diluted EPS is expected to be between $0.80 and $0.90, compared to $0.63 in 2014, based on an average fully diluted share count of approximately 33 million shares
  • Capital expenditures of between $24 and $26 million
  • Effective tax rate of approximately 33%

AMRI’s estimates for 2015 reflect the acquisition of the SSCI West Lafayette, Ind. operations, closing in February 2015, to be included in the DDS segment, as well as the Glasgow UK injectable drug product formulation operations, closed in January 2015, to be included in the Drug Product segment.

Fourth Quarter Results Conference Call

AMRI will host a conference call and webcast today at 8:30 a.m. ET to discuss fourth quarter 2014 results. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 75749093. The webcast and supplementing slides can be accessed on the company’s website at www.amriglobal.com.

A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 75749093. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company’s website at http://ir.amriglobal.com.

About AMRI 
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Solutions (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Forward-looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the company’s estimates of revenue, contract revenue, adjusted EBITDA, adjusted diluted earnings per share, and all information and other statements regarding the estimates of results and financial outlook for 2015, statements made by the company’s Chief Executive Officer, and statements under the caption “Financial Outlook,” statements regarding the business interruption event at the OsoBio facility and the time and resources involved with the remediation thereof and the impact of such event on the Company’s results of operations, statements regarding the strength of the company’s business and prospects, statements regarding the impact of recent acquisition activity, and statements concerning the company’s momentum and long-term growth, including expected results for 2015. Readers should not place undue reliance on our forward-looking statements. The company’s actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company’s control. Factors that could cause such differences include, but are not limited to, trends in pharmaceutical and biotechnology companies’ outsourcing of manufacturing services and chemical research and development, including softness in these markets; sales of Allegra® and the impact of the “at-risk” launch of generic Allegra®, the rapid reduction in royalties on the Allegra products expected in 2015 and the patent expirations on such products, the OTC conversion of Allegra® and the generic and OTC sales of Allegra in Japan on the company’s receipt of significant royalties under the Allegra® license agreement; the success of the sales of other products for which the company receives royalties; the risk that the company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra® license agreements; the risk that clients may terminate or reduce demand under any strategic or multi-year deal; the company’s ability to enforce its intellectual property and technology rights; the company’s ability to obtain financing sufficient to meet its business needs; the company’s ability to successfully comply with heightened FDA scrutiny on aseptic fill/finish operations; the results of further FDA inspections; the company’s ability to effectively maintain compliance with applicable FDA and DEA regulations; the company’s ability to integrate past or future acquisitions, including the Aptuit West Lafayette and Glasgow operations, Cedarburg Pharmaceuticals and Oso Biopharmaceuticals Manufacturing, and make such acquisitions accretive to the company’s business model, the company’s ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company’s strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 17, 2014, and the company’s other SEC filings. Revenue, contract revenue, adjusted diluted EPS, adjusted contract margin, adjusted EBITDA and other financial guidance offered by senior management today with respect to 2015 represent a point-in-time estimate and are based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release.

Non-GAAP Adjustment Items

To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit (loss), contract gross margin, income (loss) from operations, and net income (loss) and income (loss) per diluted share as adjusted to exclude certain restructuring charges, executive transition costs, convertible debt interest and amortization charges, business interruption charges, business acquisition costs, litigation settlement charges, write-offs of deferred financing costs, non-cash long-lived asset impairment charges, losses on disposals of assets related to restructuring activities, insurance demutualization gains, depreciation and amortization of purchase accounting adjustments, non-recurring income tax adjustments, and postretirement benefit plan settlement gains in the 2014 and 2013 periods. We have also presented non-GAAP measures of adjusted EBITDA, which in addition to the items excluded above, further excluded the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. Exclusion of these non-recurring items allows comparisons of operating results that are consistent over time. We believe presentation of these non-GAAP measures enhances an overall understanding of our historical financial performance because we believe they are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for income (loss) from operations, net income (loss) or income (loss) per diluted share, prepared in accordance with U.S. GAAP. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. Our projected 2015 adjusted EPS and adjusted EBITDA, however, are only provided on an adjusted basis. It is not feasible to provide GAAP EPS and EBITDA guidance because the items excluded are difficult to predict and estimate and are primarily dependent on future events.

Albany Molecular Research, Inc.

Condensed Consolidated Statements of Operations (unaudited)

Three Months Ended

Year Ended

(Dollars in thousands, except for per share data)

December 31,

December 31,

December 31,

December 31,

2014

2013

2014

2013

Contract revenue

$             80,712

$                59,715

$         250,705

$       210,001

Recurring royalties

5,888

7,407

25,866

36,574

Total revenue

86,600

67,122

276,571

246,575

Cost of contract revenue

66,131

47,103

209,193

171,923

Technology incentive award

344

513

1,621

2,767

Research and development

229

44

1,004

414

Selling, general and administrative

13,954

11,004

48,898

42,256

Postretirement benefit plan settlement gain

(1,285)

Restructuring charges

146

1,075

3,582

7,183

Impairment charges

2,885

417

7,835

1,857

Total operating expenses

83,689

60,156

270,848

226,400

Income from operations

2,911

6,966

5,723

20,175

Interest expense,  net

(2,700)

(1,000)

(10,956)

(1,244)

Other (expense) income, net

(238)

(99)

(235)

772

(Loss) income before income taxes 

(27)

5,867

(5,468)

19,703

Income tax expense (benefit) 

1,834

1,603

(2,190)

7,935

Net (loss)income 

$             (1,861)

$                  4,264

$           (3,278)

$         11,768

Basic (loss) income per share

$               (0.06)

$                    0.14

$             (0.10)

$             0.38

Diluted (loss) income per share

$               (0.06)

$                    0.13

$             (0.10)

$             0.37

 

Albany Molecular Research, Inc.

Selected Consolidated Balance Sheet Data (unaudited)

(Dollars in thousands)

December 31, 

December 31, 

2014

2013

Cash and cash equivalents………………………………………………..

$      46,995

$      175,928

Restricted cash………………………………………………………………..

4,052

714

Accounts receivable, net…………………………………………………..

71,644

52,216

Royalty income receivable…………………………………………………

5,061

7,523

Inventory…………………………………………………………………………

49,880

31,991

Total current assets………………………………………………………….

191,012

279,019

Restricted cash………………………………………………………………..

3,810

Property and equipment, net………………………………………………

165,475

127,775

Total assets…………………………………………………………………….

519,953

445,268

Total current liabilities……………………………………………………….

48,690

48,849

Long‒term debt, excluding current installments, net of unamortized  
     discount……………………………………………………………………..

159,980

123,135

Total liabilities…………………………………………………………………..

278,131

204,511

Total stockholders’ equity………………………………………………….

241,822

240,757

Total liabilities and stockholders’ equity……………………………….

519,953

445,268

Table 1: Reconciliation of three months and year ended December 31, 2014 and 2013 reported contract gross profit (loss) and contract gross margin to adjusted contract gross profit (loss) and adjusted contract gross margin

Non-GAAP Measures

Three Months Ended

Year Ended

(Dollars in thousands)

December 31,

December 31,

2014

2013

2014

2013

Consolidated Contract Revenue, as reported

$    80,712

$    59,715

$  250,705

$  210,001

Consolidated Cost of Contract Revenue, as reported

66,131

47,103

209,193

171,923

Consolidated Contract Gross Profit, as reported

14,581

12,612

41,512

38,078

add: Business interruption charges

3,328

6,445

add: Purchase accounting depreciation

331

694

add: Business acquisition costs

34

Consolidated Contract Gross Profit, as adjusted

$    18,240

$    12,612

$    48,685

$    38,078

Consolidated Contract Gross Margin, as reported

18%

21%

17%

18%

Consolidated Contract Gross Margin, as adjusted

23%

21%

19%

18%

API Segment Contract Revenue, as reported

$    46,204

$    38,301

$  144,349

$  125,871

API Segment Cost of Contract Revenue, as reported

34,200

27,975

111,873

95,144

API Segment Contract Gross Profit, as reported

12,004

10,326

32,476

30,727

add: Purchase accounting depreciation

216

406

API Segment Contract Gross Profit, as adjusted

$    12,220

$    10,326

$    32,882

$    30,727

API Segment Contract Gross Margin, as reported

26%

27%

22%

24%

API Segment Contract Gross Margin, as adjusted

26%

27%

23%

24%

Drug Product Segment Contract Revenue, as reported

$    14,767

$      3,010

$    29,619

$      6,712

Drug Product Segment Cost of Contract Revenue, as reported

16,449

3,100

34,919

10,175

Drug Product Segment Contract Gross Loss, as reported

(1,682)

(90)

(5,300)

(3,463)

add: Business interruption charges

3,328

6,445

add: Purchase accounting depreciation

115

288

add: Business acquisition costs

34

Drug Product Segment Contract Gross Profit (Loss), as adjusted

$      1,761

$          (90)

$      1,467

$     (3,463)

Drug Product Segment Contract Margin, as reported

-11%

-3%

-18%

-52%

Drug Product Segment Contract Margin, as adjusted

12%

-3%

5%

-52%

 

Table 2: Reconciliation of three months and year ended December 31, 2014 and 2013 reported income from operations, net income (loss) and earnings (loss) per diluted share to adjusted income from operations, adjusted net income and adjusted earnings per share:

(Dollars in thousands, except for per share data)

Non-GAAP Measures

QTD 

QTD

YTD 

YTD

December 31, 
2014

December 31, 
2013

December 31, 
2014

December 31, 
2013

Income from operations, as reported

$            2,911

$            6,966

$            5,723

$          20,175

Impairment charges

2,885

417

7,835

1,857

Restructuring charges

146

1,075

3,582

7,183

Business interruption charges

3,511

6,628

Executive transition costs

1,115

626

1,630

Business acquisition costs

1,083

3,721

Purchase accounting depreciation and amortization

913

MOUNTAIN VIEW, Calif., Dec. 9, 2014 /PRNewswire/ — Following the inaugural Economic Development Innovation (EDI) Council conference organized at Frost & Sullivan’s flagship Growth, Innovation & Leadership (GIL) Silicon Valley event, the Council reconvened for its first quarterly web conference on November 12th, 2014.

Logo – http://photos.prnewswire.com/prnh/20141208/162901LOGO

The web conference began with case studies on visionary leadership and its importance in economic development innovation. The Council went on to review and vote on critical issues in economic development.

Five critical economic development issues were voted to be included as part the Council’s research agenda for 2015:

  • Bridging the Digital Divide
  • Innovative Education
  • Smart Development
  • Affordable and Disruptive Healthcare
  • Attracting Investments

The Council will reconvene each quarter, encouraging members to share best practices and propagate innovative solutions to ongoing global challenges. Of the five critical issues, Bridging the Digital Divide will form the center of the Council’s focus for the first quarter of 2015. The next quarterly EDI Council web conference will take place on March 11, 2015 at 10:00 a.m. EDT.

To register for the next EDI Council web conference, click here. Join Frost & Sullivan’s Economic Development Innovation (EDI) Council Group to interact with this global community of economic development leaders.

“Visionary leadership from economic development agencies can be transformative in driving growth and solving critical issues,” said Frost & Sullivan Chairman David Frigstad. “The collaborative learning and sharing model adopted by the Council is a powerful way to address approaches to solve global challenges.”

The EDI Council also identified a set of accelerators associated with the critical issues to spur economic development. The following are the set of accelerators:

  • Digital Transformation
  • Technology Transfer and Intellectual Property Protection
  • Public Private Partnerships
  • Localized, Ownership Based, Collaborative & Leadership Driven (L.O.C.A.L) Healthcare Transformation
  • Implementation Focus & Excellence

“We are thrilled with the ability to catalyze and accelerate disruptive approaches to global change. We look to expand the breadth and scope of the EDI Council to facilitate deeper discussion, cooperation, and thought leadership,” said Frost & Sullivan’s Global Vice President- Economic Development Innovation, Sath Rao.

About the EDI Council

The Economic Development Innovation Council is a global body of Economic Development Organization (EDO) leaders who are committed to the growth and success of the EDO sector. The Council does this by uniting EDOs from across the world to deliberate on key global challenges, exchange best practices and share success stories.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Contact:
Ariel Brown
Corporate Communications – North America
P: +1.210.247.2481
F: +1.210.348.1003
E: ariel.brown@frost.com

http://www.frost.com

Photo – http://photos.prnasia.com/prnh/20141209/8521407394LOGO

NetDragon Announces Third Quarter 2014 Financial Results

– Solid YOY Top Line Growth with Strong New Game Pipeline Growth Momentum

– Education Ecosystem Product Development on Track

HONG KONG, Dec. 2, 2014 /PRNewswire/ — NetDragon Websoft Inc. (“NetDragon” or “the Company”) (Hong Kong Stock Code: 777), a leading developer and operator of online games and mobile internet platforms in China, today announced its financial results for the third quarter ended September 30, 2014 (“the Period”). A conference call and webcast is scheduled at 8 p.m. Hong Kong Time on Tuesday, December 2, 2014 to discuss the results and recent business developments.

Third quarter 2014 Financial Highlights

  • Revenue was RMB232.7 million, an increase of 1.1% quarter-over-quarter and 6.1% year-over-year.
  • Gross profit was RMB209.2 million, an increase of 0.4% quarter-over-quarter and 4.8% year-over-year.
  • Operating profit was RMB57.7 million, a decrease of 24.1% quarter-over-quarter and an increase of 15.8% year-over-year.
  • Non-GAAP[1] profit for the Period attributable to owners of the Company was RMB62.9 million
  • Profit for the Period from continuing operations was RMB52.4 million, a decrease of 17.8% quarter-over-quarter and an increase of 41.8% year-over-year.
  • Basic and diluted earnings per share were RMB10.31 cents and RMB10.27 cents, respectively.

Third quarter 2014 Operational Highlights[2]

  • Peak concurrent users (“PCU”) for online games were 382,000, a decrease of 18.9% quarter-over-quarter and 25.1% year-over-year.
  • Average concurrent users (“ACU”) for online games were 225,000, a decrease of 5.9% quarter-over-quarter and 16.7% year-over-year.
  • Average revenue per user (“ARPU”) for online games was RMB299, an increase of 1.4% from the previous quarter and 14.6% year-over-year.
  • Daily active users (“DAU”) for new micro-client game Calibur of Spirit were 1 million.

[1] See “Non-GAAP Financial Measures” section for more details on the reasons for presenting these measures

[2] the PCU and ACU data below did not include the new micro-client game Calibur of Spirit

“We achieved another quarter of solid growth as we gain strong growth momentum in our MMORPG, mobile games and online education businesses.” commented Mr. Dejian Liu, Chairman and Executive Director of NetDragon. “We are pleased that two of our newly launched games, Calibur of Spirit and Eudemons Online Pocket Version, gain strong user traction as hype surrounding Calibur of Spirit continuues to grow following its selection for the World Cyber Arena (“WCA”) held in Yinchuan in October 2014. This was not only the sole China-developed competitive game selected, but also marked NetDragon’s first game entered into the WCA – a fact that we are very proud of. Calibur of Spirit has already been able to achieve PCU of 170,000, MAU of 4 million and DAU of 1 million during the quarter, and over RMB10 million in monthly gross revenue in October 2014. With marketing and promotional activities ramping up in preparation for its official launch early next year, we are confident that revenue for this game will grow substantially in 2015. At the same time, we are excited to have concluded an agreement with Valve during the quarter to make the English version of our new 3D strategy MMO game, Tiger Knight, available on Steam in the near future once open beta-testing is completed early next year.”

“We continued to push our mobile games business forward with revenue increasing 43.8% sequentially as we take advantage of the rapid shift towards mobile globally. The Android version of Eudemons Online Pocket Version was launched in September 2014 to great reviews and has already generated solid operating metrics. We also have high hopes for the iOS version which will begin open-beta testing next quarter. We signed an exclusive licensing agreement for Blade & Sword with one of China’s leading mobile game publishers during the quarter. In overseas markets, the Arabic version of The Pirate generated record high monthly revenue.”

“We just concluded a summit on smart education which we jointly organized with East China Normal University to focus on developing educational tools for the digital age. We are developing relationships with multiple educational institutions such as Beijing Normal University and Central China Normal University as part of our broader strategy to participate in the formulation of educational standards. As part of this effort, we have been developing intelligent classroom and other educational products that will seamlessly be integrated into our overall ecosystem. We began to generate revenue from our K12 educational tablet during the quarter and look forward to further developing our total-solution educational ecosystem. We are confident our education products will provide a unique value proposition to the massive addressable market of students in China.”

Third quarter 2014 Unaudited Financial Results

Revenue

Revenue was RMB232.7 million, an increase of 1.1% from RMB230.1 million in the previous quarter and an increase of 6.1% from RMB219.4 million during the same quarter last year.

Revenue from online games and other business generated from China was RMB195.9 million, a decrease of 3.8% from RMB203.5 million in the previous quarter and an increase of 0.4% from RMB195.1 million in the same quarter last year.

Revenue from online games and other business generated from overseas markets was RMB36.8 million, an increase of 38.3% from RMB26.6 million in the previous quarter and an increase of 51.4% from RMB24.3 million in the same quarter last year. The sequential and year-over-year increases were mainly due to revenue contribution from Cherrypick’s mobile solutions business which was acquired by the Company during the third quarter of 2014.

Gross profit and gross profit margin

Gross profit was RMB209.2 million, an increase of 0.4% from RMB208.2 million in the previous quarter and an increase of 4.8% from RMB199.5 million in the same quarter last year. Gross profit margin was 89.9%, compared with 90.5% in the previous quarter and 91.0% in the same quarter last year.

Operating expenses

Selling and marketing expenses were RMB38.6 million, an increase of 14.8% from RMB33.6 million in the previous quarter and an increase of 38.1% from RMB27.9 million in the same quarter last year. The sequential and year-over-year increases in selling and marketing expenses were mainly due to increases in staff costs in relation to the rapid build-up of our education business as well as advertising and promotional expenses.

Administrative expenses were RMB77.5 million, an increase of 8.2% from RMB71.6 million in the previous quarter and a decrease of 11.5% from RMB 87.6 million in the same quarter last year. The sequential increase in administrative expenses was mainly due to increases in staff costs and depreciation of the new Changle base and amortisation of intangible assets arising from acquisition of Cherrypicks which were offset by a decrease in legal and professional fees. The year-over-year decrease was mainly due to decreases in share-based compensation and legal and professional fees which were partially offset by increases in low value consumables, depreciation and amortisation and rental expenses.

Development costs were RMB67.3 million, an increase of 30.3% from RMB51.7 million in the previous quarter and an increase of 48.5% from RMB45.3 million in the same quarter last year. The sequential increase in development costs was mainly due to an increase in R&D staff. The year-over-year increase was mainly due to increases in staff and outsourcing costs.

Other expenses were RMB3.7 million, a decrease of 77.8% from RMB16.5 million in the previous quarter. The sequential decrease in other expenses was mainly due to a one-time donation during the second quarter of 2014 to Beijing Normal University.

Operating profit

Operating profit from continuing operations was RMB57.7 million, a decrease of 24.1% from RMB76.0 million in the previous quarter and an increase of 15.8% from RMB49.8 million in the same quarter last year.

Profit for the Period from continuing operations

Profit for the Period from continuing operations was RMB52.4 million, a decrease of 17.8% from RMB63.8 million in the previous quarter and an increase of 41.8% from RMB37.0 million in the same quarter last year.

Basic and diluted earnings per share were RMB0.1031 and RMB0.1027, respectively, compared with RMB0.1254 and RMB0.1250, respectively, in the previous quarter, and RMB0.0727 and RMB0.0722, respectively, in the same quarter last year.

Liquidity

As ofSeptember 30, 2014, NetDragon had bank deposits, bank balances, cash and pledged bank deposit and liquid investments (classified as held-for-trading investments) of approximately RMB3,398.7 million, compared with RMB3,709.3 million as of June 30, 2014. Liquid investments are comprised of pre-dominantly highly liquid fixed-income investments which are used to enhance the Company’s overall strong cash position.

Share Repurchase Program

During the nine months ended September 30, 2014, the Company repurchased a total of 2,585,000 shares for an aggregate consideration of approximately HKD37.0 million before expenses.

During the month ended October 31, 2014, the Company repurchased and subsequently cancelled 2,824,500 shares for an aggregate consideration of approximately HKD37.0 million.

Third quarter 2014 Business Developments

Games

Growth momentum in the Company’s online and micro-client games business picked up during the quarter following the launch of Calibur of Spirit and Eudemons Online Pocket Version. Calibur of Spirit generated PCU of 170,000, MAU of 4 million, and DAU of 1 million during the third quarter and over RMB10 million in monthly gross revenue in October 2014. The Company expects to the see the game generate increasing returns following its official launch early next year. In September 2014, the android version of Eudemons Online Pocket Version was launched and recorded a pay rate of 6.74% and a one-day retention rate of approximately 45%.

In September 2014, the Company began closed-beta testing for Goddess Era, the Chinese expansion pack for its flagship game Eudemons Online. Slated to begin open-beta testing next quarter, the expansion pack allows players to enhance their characters’ attributes for free through the newly added ‘Goddess Gifts’ system. The Company also released Second Ninja War, a new updated version of Conquer Online that adds new skills and weapons to the game. Mecho Wars, an expansion pack for the Company’s flagship title Zero Online was launched in September 2014 and provides players with inter-server game modes and new gameplay. Talisman World, an expansion pack for Way of the Five began open-beta testing in July 2014. The expansion pack generated record monthly revenue by providing players with a refreshing new combat experience and battle mode.

Online and Mobile Education

The Company continued to make steady progress in the development of its Open Cloud-based Education Platform during the quarter. In partnership with universities, the Company drove the research progress on artificial intelligence, big data analysis and cloud computing and allowed the seamless connectivity of the educational tablet to education resources. Having established a robust back-end platform, the Company is able to provide content support to various online education applications.

Discussions to develop new content and strategic partnership for the Company’s online and mobile education business continued during the quarter. Development of the Company’s K-12 educational tablet continued as it moved through the various stages of development including the design and function of its features and content. Through the implementation of a “total solution ecosystem” product strategy, the Company is working diligently to achieve targets in the design and development of software, hardware, content and social networking components. By leveraging technology, ‘gamification’ of educational content and user behavioral analysis in the delivery of educational content, the Company is confident that the final product will be a game-changer in the way students learn.

NetDragon entered into a strategic cooperation agreement with Beijing Normal University to jointly-focus on developing new educational content and technologies. The Company plans to establish a NetDragon research center in Beijing that will focus on jointly-developing educational opportunities with Beijing Normal University. Opportunities include cooperation in the development and production of content, joint employment of senior staff, collaborative research on classroom interaction and e-textbooks. NetDragon donated US$250,000 to the Internet Learning Institute of the National Central University in Taiwan in an effort to develop smart educational tools for Chinese students in Mainland China, Taiwan, and Hong Kong during the quarter. The Company believes that its partnership with universities will broaden the supply of high-quality educational content as well as access to world class pedagogical research and practices.

The Company also signed strategic agreements with domestic and international education book publishers, working together in an effort to generate quality content for the educational tablet. In additional, it formed a strategic partnership with East China Normal University, Beijing Normal University and Huazhong Normal University to develop a unique innovative mobile education platform and worked with People’s Education Press on to support the National Science and Technology program – Research on key technology in developing education resources digital publishing and application.The Company was responsible for presenting the program’s display terminal (electronic bag), and its education tablet will serve as an pilot end device for the entire education industry.

Cooperation and Communication in the Mobile Internet Industry and Communication Technology between Fujian Province and Hong Kong

On September 5, 2014, NetDragon signed a Letter of Intent (“LOI”) with Hong Kong Cyberport Management Company Limited and Hong Kong Wireless Technology Industry Association for a term of one year. The three parties agreed to establish a strategic partnership to further grow the local information and communication technology industry. The LOI covers the following four aspects: professional training, the introduction of local mobile applications to the mainland market, internship programs, and digital classrooms. All three parties will jointly support and help Hong Kong-based IT companies and talent to promote their business in Mainland China and will provide talent training programs for them.

Strategic Merger with Cherrypicks

On June 3, 2014, NetDragon entered into a sale and purchase agreement to acquire Cherrypick’s mobile solution business. Cherrypicks is a leading enterprise in mobile technology and mobile marketing in the Asia Pacific region. The acquisition was completed on July 21, 2014. The strategic merger will provide the Company with a team of world-class, innovative mobile solutions developers with strong capabilities to build cutting edge mobile products for global markets in areas including enterprise software, mobile marketing, mobile commerce and mobile education.

Business Outlook

MMORPGs

The Company’s first micro-client in-house developed multiplayer online battle arena game, Calibur of Spirit was selected for the World Cyber Arena (“WCA”) held in at Yinchuan China in October 2014. This marks the Company’s first game selected for the WCA, and represents a solid footstep in exploring the game industry chain. Calibur of Spirit is the only China-developed competitive game selected for the WCA. The game is currently undergoing beta-testing and will begin open-beta testing in early 2015. Given the huge popularity of this game, the Company expects Calibur of Spirit to generate increased revenue for its gaming revenue in the following quarters. The Company’s new 3D action strategy MMO, Tiger Knight, was identified by the Steam Community as a game of interest during the first half of 2014. Steam is a global fully integrated digital gaming and social platform developed by Valve. In September 2014, the Company signed an agreement with Valve to make the English version of the game available on Steam in the near future. Tiger Knight is in currently undergoing testing, with open beta-testing expected to begin in early 2015.

For existing online games, the Company will continue to provide gameplay updates and new versions to increase user stickiness. NetDragon plans to release brand new expansion packs for its flagship titles, Eudemons Online and Conquer Online, in the fourth quarter of 2014 including content enhancements.

Mobile Games

  • ŸThe android version of Eudemons Online Pocket Version was officially launched in September 2014.
  • Blade & Sword, a self-developed 2.5D role playing mobile game based on martial arts, is expected to begin testing of its iOS and Android versions during the fourth quarter of 2014.
  • Waku & Maou, a real-time strategy-based collectible card mobile game featuring scenic landscapes, is currently undergoing closed-beta testing and is expected to launch during the fourth quarter of 2014.
  • Fatal Fighter, a 2D scrolling mobile combat game, began a new beta testing in October 2014 with a simplified Chinese and Arabic version expected to launch in the fourth quarter of 2014 or early 2015.
  • Martial Overlord, a 3D in-house developed martial arts mobile action game, is currently undergoing beta-testing and is expected to launch during the first quarter of 2015.

Online and Mobile Education

In cooperation with East China Normal University, the Company jointly organized the “2014 Strait Wisdom Education Forum and Education Informatization Technology Conference” held at the end of November 2014 which focused on education in the digital age. On November 27, NetDragon officially became a member of CELTSC’s Branch Council for Education Technology following approval by all members present at the Council’s general meeting. In the future, the Company will continue to participate in the formulation of standards for electronic books, bags and study rooms by cooperating with various institutions as it works to develop its educational ecosystem.

The Company expects to continue its strong progress in the development of its mobile education ecosystem product. On the hardware side, the Company is working to refine and enhance the functionality and uniqueness of its educational tablet based on user feedback gathered during the pilot launch. On the software side, NetDragon is implementing a program that will be rolled out in tandem with China’s ‘Three Access Points, Two Platforms’ program which seeks to upgrade overall information technology for educational uses. According to the program, NetDragon will build a communication platform on online study room space based on the instant messaging technology.

In November 2014, NetDragon, Beijing Normal University and a global educational content company signed a memorandum of understanding to leverage each party’s strengths to develop a leading smart education solution to support the national educational technology platform.

Non-GAAP Financial Measures

To supplement the consolidated results of the Company prepared in accordance with HKFRSs, the use of certain non-GAAP measures is provided solely to enhance the overall understanding of the Company’s current financial performance. These non-GAAP measures are not expressly permitted measures under HKFRSs and may not be comparable to similarly titled measures for other companies. The non-GAAP financial measures of the Company exclude share-based payments expense, amortization of intangible assets arising from acquisition of subsidiaries, interest income on pledged bank deposit, exchange gain (loss) on pledged bank deposit, secured bank borrowing and redeemable convertible preferred shares, net gain (loss) on derivative financial instruments and finance costs.

Management Conference Call

NetDragon will host a management conference call and webcast to review its third quarter 2014 financial results ended September 30, 2014 on Tuesday, December 2, 2014, at 8pm Hong Kong time.

Details of the live conference call are as follows:

International Toll

65-6723-9381

US Toll Free

1-866-519-4004

Hong Kong Toll Free

800-906-601

China Toll Free (for fixed line users)

800-8190-121

China Toll Free (for mobile users)

400-6208-038

Passcode

NetDragon

A live and archived webcast of the conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.netdragon.com/investor/ir_events.shtml. Participants in the live webcast should visit the aforementioned website 10 minutes prior to the call, then click on the icon for “3Q 2014 Results Conference Call” and follow the registration instructions.

About NetDragon

NetDragon Websoft Inc. (HKSE: 0777) is a leading innovator and creative force in China’s mobile internet industry. Established in 1999, NetDragon is a vertically integrated, cutting-edge R&D powerhouse with a highly successful track record which includes the development of flagship MMORPGs such as Eudemons Online and Conquer Online, China’s number one online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless, which was sold to Baidu in what was at the time the largest internet M&A transaction in China in 2013. Being a China’s pioneer in overseas expansion, NetDragon directly operates a number of game titles in over 10 languages internationally since 2003. NetDragon continues to strive for developing mobile games and software applications for users. In recent years, NetDragon has also becoming a major player in China’s online and mobile education industry as it works to leverage its mobile internet technologies and operational know-how to make fun and effective learning tools.

For investor enquiries, please contact:

NetDragon Websoft Inc.

Ms. Maggie Zhou
Senior Director of Investor Relations
Tel.: +86 591 8754 3120; +852 2850 7266
Email: maggie@nd.com.cn; ndir@nd.com.cn
Website: www.nd.com.cn/ir


CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2014

Three Months Ended

September 30, 2014

June 30, 2014

September 30, 2014

RMB ‘000

RMB ‘000

RMB ‘000

(Unaudited)

(Unaudited)

(Unaudited)

Continuing operations

Revenue

232,702

230,144

219,364

Cost of revenue

(23,530)

(21,888)

(19,837)

Gross profit

209,172

208,256

199,527

Other income and gains

36,034

41,255

12,476

Selling and marketing expenses

(38,569)

(33,590)

(27,935)

Administrative expenses

(77,538)

(71,645)

(87,611)

Development costs

(67,341)

(51,687)

(45,349)

Other expenses

(3,666)

(16,491)

(1,259)

Share of losses of associates

(406)

(145)

(41)

Operating profit

57,686

75,953

49,808

Interest income on pledged bank deposit

638

840

222

Exchange gain (loss) on pledged bank
deposit and secured bank borrowing

1,188

(2,106)

(1,769)

Net (loss) gain on derivative financial
instrument

(646)

2,737

Net (loss) gain on held-for-trading investment

(1,553)

61

Finance costs

(728)

(1,132)

(326)

Profit before taxation

56,585

76,353

47,935

Taxation

(4,166)

(12,547)

(10,974)

Profit for the period from continuing
operations

52,419

63,806

36,961

Discontinued operations

Profit for the period from discontinued
operations

105,586

Profit for the period

52,419

63,806

142,547

Other comprehensive (expense) income for
the period, net of income tax:

Exchange differences arising on translation
of foreign operations that may be
reclassified subsequently to profit or loss

(161)

29

(167)

Total comprehensive income for the period

52,258

63,835

142,380

Profit (loss) for the period attributable to:

-Owners of the Company

52,595

63,830

97,230

-Non-controlling interests

(176)

(24)

45,317

52,419

63,806

142,547

Profit for the period attributable to

owners of the Company:

-from continuing operations

52,595

63,830

36,926

-from discontinued operations

60,304

Profit for the period attributable to

owners of the Company

52,595

63,830

97,230

(Loss) profit for the period attributable to

non-controlling interests:

-from continuing operations

(176)

(24)

35

-from discontinued operations

45,282

(Loss) profit for the period attributable to

non-controlling interests

(176)

(24)

45,317

Total comprehensive income (expense)
attributable to:

-Owners of the Company

52,434

63,859

97,063

-Non-controlling interests

(176)

(24)

45,317

52,258

63,835

142,380

Earnings per share

RMB cents

RMB cents

RMB cents

From continuing and discontinued
operations

-Basic

10.31

12.54

19.14

-Diluted

10.27

12.50

19.02

From continuing operations

-Basic

10.31

12.54

7.27

-Diluted

10.27

12.50

7.22

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2014

September 30, 2014

December 31, 2013

(Unaudited)

(Audited)

RMB ‘000

RMB ‘000

Non-current assets

Property, plant and equipment

771,887

532,684

Prepaid lease payments

379,263

185,819

Investment property

15,725

Intangible assets

143,380

Interests in associates

30,510

1,299

Available-for-sale investments

5,000

5,000

Loan receivables

15,897

16,041

Deposits made for acquisition of property, plant and
equipment

19,444

16,769

Other receivable

60,969

Goodwill

18,780

12,534

Deferred tax assets

54

54

1,384,215

846,894

Current assets

Prepaid lease payments

2,708

2,583

Loan receivables

898

713

Trade receivables

52,252

41,718

Other receivables, prepayments and deposits

167,914

69,770

Amounts due from related companies

1,704

4,564

Amounts due from associates

72

Held-for-trading investments

185,884

20,735

Pledged bank deposit

107,368

Bank deposits

2,540,917

3,051,289

Bank balances and cash

671,934

1,304,355

3,624,283

4,603,095

Current liabilities

Trade and other payables

168,999

152,837

Deferred income

27,008

26,553

Amount due to a related company

340

Secured bank borrowing

104,672

Other financial liability

3,122

Income tax payable

136,505

539,927

332,852

827,111

Net current assets

3,291,431

3,775,984

Total assets less current liabilities

4,675,646

4,622,878

Non-current liabilities

Other payables

2,248

Deferred tax liabilities

51

2,299

Net assets

4,673,347

4,622,878

Capital and reserves

Share capital

37,849

37,664

Share premium and reserves

4,633,727

4,577,478

Equity attributable to owners of the Company

4,671,576

4,615,142

Non-controlling interests

1,771

7,736

4,673,347

4,622,878

 

China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2015

2Q15 Added 15,584 New Subscribers

2Q15 Revenue Up 7.4% YOY to RMB152.1 Million ($24.8 Million)

2Q15 Operating Income Increased to RMB57.5 Million ($9.4 Million)

Conference Call to be Held November 26, 2014 at 8:00 a.m. ET

HONG KONG, Nov. 26, 2014 /PRNewswire/ — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its preliminary unaudited financial results for the second quarter and first half of fiscal year 2015 ended September 30, 2014.

Second Quarter of Fiscal 2015 Highlights

  • Revenues for the second quarter of fiscal 2015 increased by 7.4% to RMB152.1 million ($24.8 million) from RMB141.6 million in the prior year period.
  • New subscriber sign-ups and accumulated subscriber base were 15,584 and 407,755, respectively.
  • Gross profit increased by 6.6% to RMB121.8 million ($19.8 million) from RMB114.3 million in the prior year period.
  • Gross margin was 80.1%, compared to 80.7% in the prior year period.
  • Operating income increased to RMB57.5 million ($9.4 million) from RMB56.3 million in the prior year period, despite higher depreciation expenses as a result of the completion of the new Guangdong and Zhejiang facilities.
  • Operating income before depreciation and amortization expenses of RMB13.3 million ($2.2 million) amounted to RMB70.8 million ($11.5 million), up 8.9% year-over-year.[1]
  • Interest expense amounted to RMB25.2 million ($4.1 million), compared to RMB16.5 million in the prior year period due to the absence of interest expense capitalization.
  • As higher interest expense was offset by lower income tax expense, net income attributable to the Company’s shareholders increased to RMB27.2 million ($4.4 million) from RMB24.9 million in the prior year period.
  • Operating cash flow for the quarter increased by 41.4% to RMB171.0 million ($27.9 million) from RMB121.0 million in the prior year period.

First Half of Fiscal 2015 Highlights

  • Revenues for the first half of fiscal 2015 increased by 13.0% to RMB305.5 million ($49.8 million) from RMB270.4 million in the prior year period.
  • New subscriber sign-up reached 31,132 and accumulated subscriber base expanded to 407,755.
  • Gross profit increased by 12.3% to RMB245.3 million ($40.0 million) from RMB218.5 million in the prior year period.
  • Operating income increased by 15.1% to RMB117.6 million ($19.2 million) from RMB102.2 million in the prior year period.
  • Operating income before depreciation and amortization expenses of RMB24.7 million ($4.0 million) amounted to RMB142.3 million ($23.2 million), up 19.1% year-over-year.[1]
  • Interest expense amounted to RMB50.1 million ($8.2 million), compared to RMB31.2 million in the prior year period due to the absence of interest expense capitalization.
  • Net income attributable to the Company’s shareholders amounted to RMB57.0 million ($9.3 million), compared to RMB57.8 million in the prior year period.
  • Operating cash flow for the first half of fiscal 2015 increased by 28.8% to RMB295.7 million ($48.2 million) from RMB229.6 million in the prior year period.

“In the second quarter, we continued to execute our sales strategy that emphasizes the one-time upfront payment option, resulting in strong operating cash flow,” stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation. “As of the end of the second quarter, our accumulated subscriber base increased 4% since last quarter and now has over four hundred thousand units, further solidifying our position as one of the largest cord blood banks on a global scale.”

Ms. Zheng further commented, “During the second quarter, we began a series of internal reorganization and marketing activities designed to strengthen the company’s industry leadership position and long-term competitive advantage. For instance, we are increasing our recruitment efforts and adjusting our remuneration policies, redeploying our sales staff for improved coverage and initiating new advertising campaigns, all of which are aimed at enhancing our overall sales operations. For the second half of fiscal 2015, our primary focus will be reinforcing these new measures that drive customer enrollment.”

Summary – Second Quarter and First Half Ended September 30, 2013 and 2014

Three Months Ended September 30,

Six Months Ended September 30,

2013

2014

2013

2014

(in thousands)

RMB

RMB

US$

RMB

RMB

US$

Revenues

141,635

152,122

24,784

270,356

305,453

49,764

Gross Profit

114,275

121,774

19,840

218,504

245,329

39,969

Operating Income

56,290

57,463

9,362

102,170

117,630

19,164

Depreciation and Amortization Expenses

8,715

13,301

2,167

17,308

24,708

4,025

Interest Expense

16,461

25,209

4,107

31,219

50,104

8,163

Net Income Attributable to the Company’s Shareholders

24,904

27,249

4,439

57,810

56,985

9,283

Earnings per Ordinary Share

0.33

0.35

0.06

0.73

0.72

0.12

– Basic[2] and Diluted (RMB/US$)

Revenue Breakdown (%)

Processing Fees

71.6%

67.4%

70.6%

68.3%

Storage Fees

28.4%

32.6%

29.4%

31.7%

New Subscribers (persons)

15,928

15,584

31,188

31,132

Total Accumulated Subscribers (persons)

343,170

407,755

343,170

407,755

Summary – Selected Cash Flow Statement Items

Three Months Ended September 30,

Six Months Ended September 30,

2013

2014

2013

2014

(in thousands)

RMB

RMB

US$

RMB

RMB

US$

Net cash provided by operating activities

120,969

171,048

27,867

229,623

295,691

48,174

Net cash used in investing activities

(17,531)

(3,998)

(651)

(56,891)

(22,395)

(3,649)

Net cash provided by financing activities

5,578

2,336

Second Quarter of Fiscal 2015 Financial Results

REVENUES. Revenues increased by 7.4% to RMB152.1 million ($24.8 million) in the second quarter of fiscal 2015 from RMB141.6 million in the prior year period, driven mainly by the increase of recurring storage revenues derived from the Company’s enlarged total subscriber base.

As the Company’s accumulated subscriber base expanded to 407,755 by the end of September 2014, revenues generated from storage fees increased to RMB49.6 million ($8.1 million), up 23.4% from RMB40.2 million in the prior year period. As a percentage of total revenues, storage fees accounted for 32.6%, compared to 28.4% in the prior year period.

Revenues generated from processing fees in the second quarter were RMB102.5 million ($16.7 million), up modestly from RMB101.4 million in the prior year period due mainly to the year-over-year difference in processing fees for the contracts signed between the two quarters. 15,584 new subscriber sign-ups were recorded during the second quarter of fiscal 2015, representing a slight decrease from 15,928 in the prior year period but slight improvement from the first quarter of fiscal 2015. Revenues generated from processing fees accounted for 67.4% of total revenues, compared to 71.6% in the prior year period.

GROSS PROFIT. Gross profit for the second quarter of fiscal 2015 increased by 6.6% to RMB121.8 million ($19.8 million) from RMB114.3 million in the prior year period, mainly due to increased revenues and well-controlled direct costs. Despite the increase in depreciation expenses, the Company continued to report a solid gross margin of 80.1%, compared to 80.7% in the prior year period.

OPERATING INCOME. Operating income for the second quarter increased at a slower pace to RMB57.5 million ($9.4 million) from RMB56.3 million in the prior year period, as a result of higher depreciation expenses. Operating margin in this quarter was 37.8%, compared to 39.7% in the prior year period. Depreciation and amortization expenses for the second quarter were RMB13.3 million ($2.2 million), compared to RMB8.7 million in the prior year period. Operating income before depreciation and amortization expenses totaled RMB70.8 million ($11.5 million), up 8.9% compared to the prior year period.[3]

Research and Development Expenses. Research and development expenses, which have been stable in the last few quarters, were RMB2.3 million ($0.4 million).

Sales and Marketing Expenses. Sales and marketing expenses for the second quarter amounted to RMB31.0 million ($5.0 million), compared to RMB27.6 million in the prior year period. As a percentage of revenue, sales and marketing expenses were 20.3%, up from 19.5% in the prior year period but down from 20.7% in the first quarter of the current fiscal year. Sales and marketing expenses continued to be correlated with the Company’s revenue performance. Looking ahead, the CCBC management team intends to further expand its sales force and marketing and promotion activities to continue to increase public awareness of cord blood banking.

General and Administrative Expenses. General and administrative expenses for the second quarter were RMB31.0 million ($5.1 million), compared to RMB28.0 million in the prior year period. Increased depreciation expenses and repair and maintenance fees contributed to the increase in general and administrative expenses. As a percentage of revenue, general and administrative expenses were 20.4%, compared to 19.8% in the prior year period.

OTHER INCOME AND EXPENSES.

Interest Expense. Interest expense is mainly related to the Company’s outstanding convertible notes. In the current quarter, the Company incurred interest expense of RMB25.2 million ($4.1 million), without any capitalization. For the prior year period, interest expense was RMB16.5 million as RMB6.8 million of interest expense was capitalized for the construction of the Company’s new facilities in Zhejiang and Guangdong.

NET INCOME ATTRIBUTABLE TO THE COMPANY’S SHAREHOLDERS. Due to higher interest expense, income before tax for the second quarter decreased year-over-year to RMB37.5 million ($6.1 million) from RMB44.7 million. However, net income attributable to the Company’s shareholders for the second quarter of fiscal 2015 increased to RMB27.2 million ($4.4 million) from RMB24.9 million in the prior year period mainly due to lower income tax expense. Net margin for the second quarter of fiscal 2015 was 17.9%.

EARNINGS PER SHARE. The terms of the convertible notes issued to KKR and Golden Meditech provide each party with the ability to participate in any Excess Cash Dividend[4]. Therefore, the calculation of basic and diluted EPS has taken into consideration the effect of such participating rights, which was RMB0.02 ($0.003) per share. Basic and diluted earnings per ordinary share for the second quarter of fiscal 2015 were RMB0.35 ($0.06).

LIQUIDITY. As of September 30, 2014, the Company had cash and cash equivalents of RMB2,156.5 million ($351.3 million) compared to RMB1,882.9 million as of March 31, 2014. The Company had total debt of RMB857.2 million ($139.7 million) as of September 30, 2014. Operating cash flow for the second quarter of fiscal 2015 increased by 41.4% to RMB171.0 million ($27.9 million) from RMB121.0 million in the prior year period.

First Half of Fiscal 2015 Financial Results

For the first half of fiscal 2015, total revenues increased by 13.0% to RMB305.5 million ($49.8 million) from RMB270.4 million in the prior year period. The increase was largely attributable to the increase of the Company’s storage revenue from the Company’s expanded subscriber base, which reached 407,755 units by the end of September 2014. Revenues from processing fees and storage fees grew by 9.3% and 21.8%, respectively. Gross profit increased by 12.3% to RMB245.3 million ($40.0 million) from RMB218.5 million in the prior year period. Operating income increased by 15.1% to RMB117.6 million ($19.2 million) from RMB102.2 million in the prior year period. Operating income before depreciation and amortization expenses totaled RMB142.3 million ($23.2 million), up 19.1% compared to the prior year period.[5] Net income attributable to the Company’s shareholders amounted to RMB57.0 million ($9.3 million). Basic and diluted earnings per share attributable to ordinary shares were RMB0.72 ($0.12). Net cash provided by operating activities in the first half of fiscal 2015 was RMB295.7 million ($48.2 million).

Conference Call

The Company will host a conference call at 8:00 a.m. ET on Wednesday, November 26, 2014 to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company’s IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above. Listeners can also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers, or +852-5808-3202 for Hong Kong callers, access code: 7331700.

Use of Non-GAAP Financial Measures

GAAP results for the three months and six months ended September 30, 2014 include non-cash item related to depreciation and amortization expenses. To supplement the Company’s unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure from U.S. GAAP; however, the Company’s management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company’s historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating our actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity, presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 of this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company’s future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including revisions to China’s One Child Policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in China, as well as general economic conditions; compliance with restrictive debt covenants under our senior convertible notes; and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending September 30, 2014 were made at the noon buying rate of RMB6.1380 to $1.00 on September 30, 2014 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com

 

EXHIBIT 1

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and September 30, 2014

March 31,

September 30,

2014

2014

RMB

RMB

US$

(in thousands except share data)

ASSETS

Current assets

Cash and cash equivalents

1,882,901

2,156,527

351,340

Accounts receivable, less allowance for doubtful accounts

(March 31, 2014: RMB20,322; September 30, 2014: RMB23,691)

95,273

110,412

17,988

Inventories

31,583

25,611

4,172

Prepaid expenses and other receivables

37,010

16,712

2,723

Debt issuance costs

3,616

3,608

588

Deferred tax assets

7,664

8,578

1,398

Total current assets

2,058,047

2,321,448

378,209

Property, plant and equipment, net

626,632

616,545

100,446

Non-current prepayments

208,894

208,429

33,957

Non-current accounts receivable, less allowance for doubtful

accounts (March 31, 2014: RMB42,703; September 30, 2014:

RMB48,300)

225,496

211,805

34,507

Inventories

48,385

54,062

8,808

Intangible assets, net

120,549

118,239

19,263

Available-for-sale equity securities

144,247

139,637

22,750

Other investment

189,129

189,129

30,813

Debt issuance costs

7,854

6,028

982

Deferred tax assets

1,789

2,648

431

Total assets

3,631,022

3,867,970

630,166

LIABILITIES

Current liabilities

Bank loan

60,000

60,000

9,775

Accounts payable

10,422

15,624

2,545

Accrued expenses and other payables

102,559

77,625

12,647

Deferred revenue

196,432

208,151

33,912

Amounts due to related parties

21,453

22,245

3,624

Income tax payable

2,571

7,202

1,173

Deferred tax liabilities

3,900

6,500

1,059

Total current liabilities

397,337

397,347

64,735

Convertible notes

777,753

797,227

129,884

Non-current deferred revenue

823,921

962,574

156,822

Other non-current liabilities

164,077

189,529

30,878

Deferred tax liabilities

27,938

27,331

4,453

Total liabilities

2,191,026

2,374,008

386,772

EQUITY

Shareholders’ equity of China Cord Blood Corporation

Ordinary shares

– US$0.0001 par value, 250,000,000 shares authorized,

50

50

8

73,140,147 shares issued, and 73,003,248 shares outstanding

as of March 31 and September 30, 2014, respectively

Additional paid-in capital

798,221

798,221

130,046

Treasury stock, at cost

(2,815)

(2,815)

(459)

(March 31 and September 30, 2014: 136,899 shares,

respectively)

Accumulated other comprehensive income

84,263

81,393

13,260

Retained earnings

555,323

612,308

99,756

Total equity attributable to China Cord Blood Corporation

1,435,042

1,489,157

242,611

Non-controlling interests

4,954

4,805

783

Total equity

1,439,996

1,493,962

243,394

Total liabilities and equity

3,631,022

3,867,970

630,166

EXHIBIT 2

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Six Months ended September 30, 2013 and 2014

Three months ended

Six months ended

September 30,

September 30,

2013

2014

2013

2014

RMB

RMB

US$

RMB

RMB

US$

(in thousands except per share data)

Revenues

141,635

152,122

24,784

270,356

305,453

49,764

Direct costs

(27,360)

(30,348)

(4,944)

(51,852)

(60,124)

(9,795)

Gross profit

114,275

121,774

19,840

218,504

245,329

39,969

Operating expenses

Research and development

(2,310)

(2,330)

(380)

(4,833)

(4,829)

(787)

Sales and marketing

(27,633)

(30,953)

(5,043)

(56,057)

(62,696)

(10,214)

General and administrative

(28,042)

(31,028)

(5,055)

(55,444)

(60,174)

(9,804)

Total operating expenses

(57,985)

(64,311)

(10,478)

(116,334)

(127,699)

(20,805)

Operating income

56,290

57,463

9,362

102,170

117,630

19,164

Other expense, net

Interest income

4,312

4,704

766

8,494

8,970

1,461

Interest expense

(16,461)

(25,209)

(4,107)

(31,219)

(50,104)

(8,163)

Exchange gain/(loss)

69

(182)

(30)

(55)

(2)

Dividend income

8,722

1,196

195

Others

514

680

111

1,044

1,297

211

Total other expense, net

(11,566)

(20,007)

(3,260)

(13,014)

(38,643)

(6,296)

Income before income tax

44,724

37,456

6,102

89,156

78,987

12,868

Income tax expense

(19,706)

(10,214)

(1,664)

(31,079)

(22,151)

(3,609)

Net income

25,018

27,242

4,438

58,077

56,836

9,259

Net Income attributable to non-controlling interests

(114)

7

1

(267)

149

24

Net income attributable to China Cord Blood Corporation’s shareholders

24,904

27,249

4,439

57,810

56,985

9,283

Net income per share:

Attributable to ordinary shares

– Basic

0.33

0.35

0.06

0.73

0.72

0.12

– Diluted

0.33

0.35

0.06

0.73

0.72

0.12

Other comprehensive income

– Net effect of foreign currency translation, net of nil tax

2,789

913

149

9,594

1,442

235

– Net unrealized gain/(loss) in available-for-sale equity securities, net of nil tax

59,220

(8,818)

(1,437)

83,558

(4,312)

(703)

Comprehensive income

87,027

19,337

3,150

151,229

53,966

8,791

Comprehensive income attributable to non-controlling interests

(114)

7

1

(267)

149

24

Comprehensive income attributable to China Cord Blood Corporation’s shareholders

86,913

19,344

3,151

150,962

54,115

8,815

EXHIBIT 3

CHINA CORD BLOOD CORPORATION

RECONCILIATION OF NON-GAAP OPERATING INCOME

For the Three Months and Six Months ended September 30, 2013 and 2014

Three months ended

Six months ended

September 30,

September 30,

2013

2014

2013

2014

RMB

RMB

US$

RMB

RMB

US$

(in thousands)

GAAP amount

<

China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2015 Financial Results

Earnings Call Scheduled for 8:00 a.m. ET on November 26, 2014

HONG KONG, Nov. 18, 2014 /PRNewswire/ — China Cord Blood Corporation (NYSE: CO) (the “Company”) today announced its plan to release financial results for the second quarter and first half of fiscal year 2015 on Tuesday, November 25, 2014, after market close in the US. 

The Company will host a conference call at 8:00 a.m. ET on Wednesday, November 26, 2014 to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company’s IR website at http://ir.chinacordbloodcorp.com/. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 7331700.

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the second quarter and first half of fiscal 2015 earnings press release will be available at http://www.chinacordbloodcorp.com/, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Tuesday, November 25, 2014 and in the Company’s Report on Form 6-K for the month of November 2014 available on the Securities and Exchange Commission’s website at http://www.sec.gov/.  

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company’s website at http://www.chinacordbloodcorp.com/.  

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com   

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: william.zima@icrinc.com

NetDragon Websoft Inc. to Report Third Quarter 2014 Financial Results on December 2, 2014

HONG KONG, Nov. 10, 2014 /PRNewswire/ — NetDragon Websoft Inc. (“NetDragon”; Stock Code: 777), a leading developer and operator of online games and mobile Internet platforms in China, today announced that it will report its financial results for the third quarter ended September 30, 2014 on Tuesday, December 2, 2014, after the close of the Hong Kong stock market.

NetDragon’s management will host an earnings conference call and live webcast to discuss the results at 8:00 PM on December 2, 2014 Hong Kong Time.

Dial-in details for the earnings conference call are as follows:

Time: 8:00 PM Beijing / Hong Kong Time / 7:00 AM Eastern Standard Time, December 2, 2014 

International Toll                                    +65-6723-9381
US Toll Free                                          + 0-808-234-6646
Hong Kong Toll Free                             +800-906-601
China Toll Free (for fixed line users)     +800-8190-121
China Toll Free (for mobile users)         +400-6208-038
Passcode                                               NetDragon

A live and archived webcast of the earnings conference call will be available on the Investor Relations section of NetDragon’s website at http://ir.netdragon.com/investor/ir_events.shtml. Participants in the live webcast should login 10 minutes prior to the call by clicking on the icon for “3Q 2014 Results Conference Call” and following the registration instructions.

About NetDragon

NetDragon Websoft Inc. (HKSE: 0777) is a leading innovator and creative force in China’s mobile Internet industry. Established in 1999, NetDragon is a vertically integrated, cutting-edge R&D powerhouse with a highly successful track record which includes the development of flagship MMORPGs such as Eudemons Online and Conquer Online, China’s number one online gaming portal, 17173.com, and China’s most influential smartphone app store platform, 91 Wireless, which was sold to Baidu in what was at the time the largest Internet M&A transaction in China in 2013. Being a China’s pioneer in overseas expansion, NetDragon directly operates a number of game titles in over 10 languages internationally since 2003. NetDragon continues to strive for developing mobile games and software applications for users. In recent years, NetDragon has also becoming a major player in China’s online and mobile education industry as it works to leverage its mobile Internet technologies and operational know-how to make fun and effective learning tools.

For investor enquiries, please contact:

NetDragon Websoft Inc.
Ms. Maggie Zhou
Senior Director of Investor Relations
Tel: +852-2850-7266 / +86-591-8754-3120
Email: maggie@nd.com.cn; ndir@nd.com.cn 
Website: www.nd.com.cn/ir

AMRI Announces Third Quarter 2014 Results

– Third quarter contract revenue of $57.5 million, up 8% from 2013

– Lower Discovery and API revenue is offset by addition of OsoBio

– OsoBio business interruption contributes to third quarter adjusted loss per share of $(0.02)

– Full year 2014 contract revenue expected to be between $253 and $261 million, an increase of 22% at the midpoint

– Full year adjusted diluted EPS range between $0.67 and $0.73, compared to $0.70 in 2013

– Company provides initial 2015 outlook

– Company creates new Drug Product reporting segment to reflect addition of OsoBio

ALBANY, N.Y., Nov. 5, 2014 /PRNewswire/ — AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter ended September 30, 2014.

Total revenue for the third quarter of 2014 was $62.5 million, an increase of 3% compared to total revenue of $60.8 million reported in the third quarter of 2013.

Total contract revenue for the third quarter of 2014 was $57.5 million, an increase of 8% compared to contract revenue of $53.0 million reported in the third quarter of 2013. Adjusted contract margins were 8% for the third quarter of 2014, compared with 16% for the third quarter of 2013, driven by lower capacity utilization, including the impact of a business interruption event at the company’s Albuquerque manufacturing facility. For a reconciliation of U.S. GAAP contract margins as reported to adjusted contract margins for the 2014 and 2013 reporting periods, please see Table 1 at the end of press release.

Royalty revenue in the third quarter of 2014 was $5.0 million, a decrease of 35% from $7.7 million in the third quarter of 2013. Royalty revenue for the third quarter of 2014 includes royalties from the Allegra® products as well as $2.4 million from the net sales of certain amphetamine salts sold by Actavis.

Net loss under U.S. GAAP was $(8.6) million, or $(0.27) per share, in the third quarter of 2014, compared to U.S. GAAP net income of $3.7 million, or $0.12 per diluted share for the third quarter of 2013. Net loss on an adjusted basis in the third quarter of 2014 was $(0.7) million or $(0.02) per share, compared to adjusted net income of $4.1 million or $0.13 per diluted share. Net loss on an adjusted basis excludes the following items that are included under U.S. GAAP: business interruption charges, restructuring and impairment charges, convertible debt interest and amortization charges, business acquisition costs, executive transition costs, postretirement benefit plan settlement gains, write-offs of deferred financing costs, non-recurring income tax adjustments, litigation settlements, insurance demutualization gains, losses on disposals of fixed assets related to restructuring activities, and depreciation and amortization of purchase accounting adjustments. For a reconciliation of U.S. GAAP net income (loss) and earnings (loss) per diluted share as reported to adjusted net income (loss) and earnings (loss) per diluted share for the 2014 and 2013 reporting periods, please see Table 2 at the end of this press release.

“The confluence of a business interruption event at our OsoBio facility, together with lower Discovery and API revenue has resulted in a weak third quarter,” said William S. Marth, AMRI’s President and Chief Executive Officer. “In our Discovery business, we saw lower fee-for-service work, while in our API business, timing of shipments impacted our results this quarter. Additionally, a weather-related power interruption at our OsoBio facility in Albuquerque took the facility offline for a period of time, contributing to the loss of finished product and the need to remediate one of the suites at the facility. Costs associated with this activity – together with facility downtime – increased our operating costs and contributed to the quarterly earnings loss. We have been working closely with our customers to not only provide a continued supply of product during this disruption, but have also taken steps to upgrade the facility to ensure we can supply our customers’ growing needs longer term. We anticipate the affected suite at our Albuquerque facility to be back online in mid-November.

“While we did not produce the results we expected this quarter, we remain confident in our outlook for the fourth quarter and 2015,” continued Mr. Marth. “We have taken significant actions this year to enhance our operations and align our resources with our customers’ needs. Our DDS insourcing programs continue to generate significant interest and we continue to see high demand for our development services. In addition, demand for complex API and Drug Product manufacturing continues to significantly expand.”

Year-to-Date Results

Total revenue for the nine-month period ended September 30, 2014 was $190.0 million, an increase of 6% compared to total revenue of $179.5 million for the same period in 2013.

Total contract revenue for the first nine months of 2014 was $170.0 million, an increase of 13% compared to contract revenue of $150.3 million for the same period in 2013. Adjusted contract margins were 18% for the nine months of 2014, consistent with the same period in 2013.

Royalty revenue for the first nine months of 2014 was $20.0 million, a decrease of 32% from $29.2 million in 2013, in line with expectations. Royalty revenue for the nine-month period ended September 30, 2014 includes royalties from the Allegra® products as well as $7.2 million from the net sales of certain amphetamine salts sold by Actavis.

Net loss under U.S. GAAP for the first nine months of 2014 was $(1.4) million, or $(0.05) per diluted share, compared to U.S. GAAP net income of $7.5 million, or $0.24 per diluted share for the first nine months of 2013. Net income on an adjusted basis in the first nine months of 2014 was $11.5 million or $0.35 per diluted share, compared to adjusted net income of $14.7 million or $0.46 per share in 2013.

For a reconciliation of U.S. GAAP net income and earnings per diluted share as reported to adjusted net income and earnings per diluted share for the 2014 and 2013 reporting periods, please see Table 2 at the end of this press release. Financial results for the three and nine months ended September 30, 2013 have been updated from previously reported amounts to reflect prior period income tax adjustments identified during the second quarter of 2014. The company considers the adjustments to be immaterial to the impacted periods.

Segment Results

In conjunction with the acquisition of OsoBio and resulting growth of its Drug Product business, AMRI is presenting its operating results in three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product. Results for the three and nine months ended September 30, 2013 reflect these changes to the reporting segments.

Drug Discovery and Development Services (DDS)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(Unaudited; $ in thousands)

2014

2013

2014

2013

DDS Contract Revenue

$ 17,982

$ 19,402

$ 56,995

$ 59,011

Cost of Contract Revenue

14,829

16,858

46,905

50,581

Contract Gross Profit

3,153

2,544

10,090

8,430

Contract Gross Margin

17.5%

13.1%

17.7%

14.3%

Discovery and Development Services (DDS) contract revenue for the third quarter of 2014 decreased 7.3% compared to the third quarter of 2013, primarily due to a decline in U.S. Discovery Services. DDS gross margins increased 4.4% as compared to the third quarter of 2013, driven by the benefit of cost-reduction initiatives and facility optimization.

Active Pharmaceutical Ingredients (API)

Three Months Ended

Nine Months Ended

September 30,

September 30,

(Unaudited; $ in thousands)

2014

2013

2014

2013

API Contract Revenue

$ 29,674

$ 31,793

$ 98,146

$ 87,573

Cost of Contract Revenue

29,000

24,990

77,685

67,164

Contract Gross Profit

674

6,803

$ 20,461

20,409

Contract Gross Margin

2.3%

21.4%

20.8%

23.3%

Adjusted Contract Gross Profit1

769

6,803

20,651

20,409

Adjusted Contract Gross Margin1

2.6%

21.4%

21.0%

23.3%

(1) Refer to Table 1 included in this release for the reconciliation of U.S. GAAP contract gross profit and contract gross margin to adjusted gross profit and adjusted gross margin as a percentage of net revenue.

API contract revenue for the third quarter of 2014 decreased 6.7% compared to the same period of 2013 due primarily to timing of API shipments to customers, offset partly by the addition of Cedarburg Pharmaceuticals. API adjusted contract margins for the third quarter of 2014 decreased 18.8% compared to the same period of 2013, primarily due to lower capacity utilization and a weaker mix of business.

Drug Product Manufacturing

Three Months Ended

Nine Months Ended

September 30,

September 30,

(Unaudited; $ in thousands)

2014

2013

2014

2013

Drug Product Contract Revenue

$ 9,825

$ 1,834

$ 14,852

$ 3,702

Cost of Contract Revenue

12,585

2,700

18,472

7,075

Contract Gross Loss

(2,760)

(866)

(3,620)

(3,373)

Contract Gross Margin

-28.1%

-47.2%

-24.4%

-91.1%

Adjusted Contract Gross Profit (Loss)1

564

(866)

(296)

(3,373)

Adjusted Contract Gross Margin1

5.7%

-47.2%

-2.0%

-91.1%

(1) Refer to Table 1 included in this release for the reconciliation of U.S. GAAP contract gross loss and contract gross margin to adjusted contract gross profit (loss) and adjusted contract gross margin as a percentage of net revenue.

Drug Product Manufacturing contract revenue for the third quarter of 2014 increased $8.0 million over the same period of 2013 and includes $6.5 million of revenue from Oso Biopharmaceuticals Manufacturing (OsoBio) that was acquired in July 2014. Drug Product adjusted contract margins for the third quarter of 2014 increased 52.9% compared to the same period of 2013, driven by volume increases, improved mix and the addition of the OsoBio business, however, contract margins were materially impacted by lower capacity utilization at the Company’s Albuquerque facility as a result of the business interruption.

Liquidity and Capital Resources

At September 30, 2014, AMRI had cash, cash equivalents and restricted cash of $23.9 million, compared to $136.9 million at June 30, 2014. The decrease in cash and cash equivalents for the quarter ended September 30, 2014 was primarily due to the use of $107.0 million to acquire the OsoBio business, and $5.6 million of capital expenditures. Total common shares outstanding, net of treasury shares, were 32,540,156 at September 30, 2014.

Financial Outlook

AMRI’s estimates for the full year 2014 and 2015 are based on actual results for the first nine months of 2014 and management’s expectations for the balance of 2014 and its outlook for 2015.

AMRI estimates the following for full year 2014:

  • Full year contract revenue is expected to be between $253 and $261 million, an increase of 22.4% at the midpoint
  • Royalty revenue of $25 million remains unchanged
  • Adjusted EBITDA between $50 and $52 million, up 7% at the midpoint
  • Adjusted diluted EPS is expected to be between $0.67 and $0.73, compared to $0.70 in 2013, based on an average fully diluted share count of approximately 32.6 million shares
  • Operating cash between $12 and $16 million and capital expenditures of approximately $16 million

AMRI estimates the following for full year 2015:

  • Full year contract revenue is expected to be between $310 and $345 million, an increase of 27% at the midpoint.
  • Royalty revenue of approximately $15 million

AMRI will provide additional guidance for 2015 as part of its fourth quarter and full year 2014 earnings presentation in February 2015.

Third Quarter Results Conference Call

The conference call can be accessed by dialing 800-723-6575 (domestic calls) or +1-785-830-1997 (international calls) at 8:30 a.m. ET and entering passcode 8919999. The audio webcast will be available live via the Internet and can be accessed on the Company’s website at http://www.amriglobal.com.

Replay of the conference call can be accessed by dialing 888-203-1112 (domestic calls) or +1-719-457-0820 (international calls) and entering passcode 8919999 from Wednesday, November 5, 2014 at 12:30 p.m. ET to Thursday, November 6, 2014 at 12:30 p.m. ET. Replay of the audio webcast can also be accessed for up to 90 days after the call via the investor area of the Company’s website at http://ir.amriglobal.com.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports pre-clinical through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at http://www.amriglobal.com or follow us on Twitter (@amriglobal).

Forward-looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include, but are not limited to, statements regarding the Company’s estimates of revenue, contract revenue, adjusted EBITDA, adjusted diluted earnings per share and segment results for the full year 2014, estimates of results for 2015, statements made by the Company’s Chief Executive Officer, and statements under the caption “Financial Outlook,” statements regarding the business interruption event at the OsoBio facility and the time and resources involved with the remediation thereof and the impact of such event on the Company’s results of operations, statements regarding the strength of the Company’s business and prospects, statements regarding the impact of recent acquisition activity, and statements concerning the Company’s momentum and long-term growth, including expected results for 2014. Readers should not place undue reliance on our forward-looking statements. The Company’s actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company’s control. Factors that could cause such differences include, but are not limited to, the actual efforts, including spending and facility downtime, associated with remediation of the business interruption event at OsoBio, adverse impacts on customer relationships due to the business interruption event at OsoBio, trends in pharmaceutical and biotechnology companies’ outsourcing of chemical research and development, including softness in these markets; sales of Allegra® and the impact of the “at-risk” launch of generic Allegra®, the OTC conversion of Allegra® and the generic and OTC sales of Allegra in Japan on the Company’s receipt of significant royalties under the Allegra® license agreement; the success of the sales of other products for which the Company receives royalties; the risk that the Company will not be able to replicate either in the short or long term the revenue stream that has been derived from the royalties payable under the Allegra® license agreements; the risk that clients may terminate or reduce demand under any strategic or multi-year deal; the Company’s ability to enforce its intellectual property and technology rights; the Company’s ability to obtain financing sufficient to meet its business needs; the Company’s ability to successfully comply with heightened FDA scrutiny on aseptic fill/finish operations; the results of further FDA inspections; the Company’s ability to effectively maintain compliance with applicable FDA and DEA regulations; the Company’s ability to integrate past or future acquisitions, including Cedarburg Pharmaceuticals and Oso Biopharmaceuticals Manufacturing, and make such acquisitions accretive to the company’s business model, the company’s ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company’s strategic investments and acquisitions to perform as expected, as well as those risks discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission on March 17, 2014, and the company’s other SEC filings. Revenue, contract revenue, adjusted diluted EPS, adjusted EBITDA and other financial guidance offered by senior management today with respect to 2014 and 2015 represent a point-in-time estimate and are based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release.

Non-GAAP Adjustment Items

To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit (loss), contract gross margin, income (loss) from operations, and net income (loss) and income (loss) per diluted share as adjusted to exclude certain restructuring charges, executive transition costs, convertible debt interest and amortization charges, business interruption charges, business acquisition costs, litigation settlement charges, write-offs of deferred financing costs, non-cash long-lived asset impairment charges, losses on disposals of assets related to restructuring activities, insurance demutualization gains, depreciation and amortization of purchase accounting adjustments, non-recurring income tax adjustments, and postretirement benefit plan settlement gains in the 2014 and 2013 periods. We have also presented non-GAAP measures of adjusted EBITDA, which in addition to the items excluded above, further excluded the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. Exclusion of these non-recurring items allows comparisons of operating results that are consistent over time. We believe presentation of these non-GAAP measures enhances an overall understanding of our historical financial performance because we believe they are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for income (loss) from operations, net income (loss) or income (loss) per diluted share, prepared in accordance with U.S. GAAP. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. Our projected 2014 adjusted EPS and 2014 and 2015 adjusted EBITDA, however, are only provided on an adjusted basis. It is not feasible to provide GAAP EPS and EBITDA guidance because the items excluded are difficult to predict and estimate and are primarily dependent on future events.

Albany Molecular Research, Inc.

Condensed Consolidated Statements of Operations (unaudited)

Three Months Ended

Nine Months Ended

(Dollars in thousands, except for per share data)

September 30,
2014

September 30,
2013

September 30,
2014

September 30,
2013

Contract revenue

$ 57,481

$ 53,029

$ 169,993

$ 150,286

Recurring royalties

4,990

7,726

19,978

29,167

Total revenue

62,471

60,755

189,971

179,453

Cost of contract revenue

56,414

44,548

143,062

124,820

Technology incentive award

260

571

1,277

2,254

Research and development

568

94

775

370

Selling, general and administrative

11,568

9,249

34,944

31,252

Postretirement benefit plan settlement gain

(1,285)

Restructuring charges

2,164

276

3,436

6,108

Property and equipment impairment charges

1,232

4,950

1,440

Total operating expenses

72,206

54,738

187,159

166,244

(Loss) income from operations

(9,735)

6,017

2,812

13,209

Interest expense, net

(2,575)

(138)

(8,256)

(411)

Other income, net

235

155

3

1,038

(Loss) income before income taxes

(12,075)

6,034

(5,441)

13,836

Income tax (benefit) expense

(3,434)

2,332

(4,024)

6,332

Net (loss) income

$ (8,641)

$ 3,702

$ (1,417)

$ 7,504

Basic (loss) income per share

$ (0.27)

$ 0.12

$ (0.05)

$ 0.24

Diluted (loss) income per share

$ (0.27)

$ 0.12

$ (0.05)

$ 0.24

Albany Molecular Research, Inc

Selected Consolidated Balance Sheet Data(unaudited)

(Dollars in thousands)

September 30,
2014

December 31,
2013

Cash and cash equivalents

$ 18,416

$ 175,928

Restricted cash

5,483

714

Accounts receivable, net

56,205

52,216

Royalty income receivable

4,987

7,523

Inventory

56,020

31,991

Total current assets

158,976

279,019

Restricted cash

3,810

Property and equipment, net

165,926

127,775

Total assets

533,036

445,268

Total current liabilities

54,634

48,849

Long‑term debt, excluding current installments, net of unamortized discount

123,571

123,135

Total liabilities

287,837

204,511

Total stockholders’ equity

245,199

240,757

Total liabilities and stockholders’ equity

533,036

445,268

Table 1: Reconciliation of three and nine months ended September 30, 2014 and 2013 reported contract gross profit (loss) and contract gross margin to adjusted contract gross profit (loss) and adjusted contract gross margin

Non-GAAP Measures

Three Months Ended

Nine Months Ended

(Dollars in thousands)

September 30,

September 30,

2014

2013

2014

2013

Consolidated Contract Revenue, as reported

$ 57,481

$ 53,029

$ 169,993

$ 150,286

Consolidated Cost of Contract Revenue, as reported

56,414

44,548

143,062

124,820

Consolidated Contract Gross Profit, as reported

1,067

8,481

26,931

25,466

add: Business interruption charges

3,117

3,117

add: Purchase accounting depreciation

268

363

add: Business acquistion costs

34

34

Consolidated Contract Gross Profit, as adjusted

$ 4,486

$ 8,481

$ 30,445

$ 25,466

Consolidated Contract Gross Margin, as reported

1.9%

16.0%

15.8%

16.9%

Consolidated Contract Gross Margin, as adjusted

7.8%

16.0%

17.9%

16.9%

API Segment Contract Revenue, as reported

$ 29,674

$ 31,793

$ 98,146

$ 87,573

API Segment Cost of Contract Revenue, as reported

29,000

24,990

77,685

67,164

API Segment Contract Gross Profit, as reported

674

6,803

20,461

20,409

add: Purchase accounting depreciation

95

190

API Segment Contract Gross Profit, as adjusted

$ 769

$ 6,803

$ 20,651

$ 20,409

API Segment Contract Gross Margin, as reported

2.3%

21.4%

20.8%

23.3%

API Segment Contract Gross Margin, as adjusted

2.6%

21.4%

21.0%

23.3%

Drug Product Segment Contract Revenue, as reported

$ 9,825

$ 1,834

$ 14,852

$ 3,702

Drug Product Segment Cost of Contract Revenue, as reported

12,585

2,700

18,472

7,075

Drug Product Segment Contract Gross Loss, as reported

(2,760)

(866)

(3,620)

(3,373)

add: Business interruption charges

3,117

3,117

add: Purchase accounting depreciation

173

173

add: Business acquisition costs

34

34

Drug Product Segment Contract Gross Profit (Loss), as adjusted

$ 564

$ (866)

$ (296)

$ (3,373)

Drug Product Segment Contract Margin, as reported

-28.1%

-47.2%

-24.4%

-91.1%

Drug Product Segment Contract Margin, as adjusted

5.7%

-47.2%

-2.0%

-91.1%

Table 2: Reconciliation of three and nine months ended September 30, 2014 and 2013 reported income (loss) from operations, net income (loss) and earnings (loss) per diluted share to adjusted income from operations, adjusted net income and adjusted earnings per share:

(Dollars in thousands, except for per share data)

Non-GAAP Measures

QTD

QTD

YTD

YTD

September 30,
2014

September 30,
2013

September 30,
2014

September 30,
2013

(Loss) income from operations, as reported

$ (9,735)

$ 6,017

$ 2,812

$ 13,209

Impairment charges

1,232

4,950

1,440

Restructuring charges

2,164

276

3,436

6,108

Business interruption charges

3,117

3,117

Executive transition costs

129

626

515

Business acquisition costs

970

2,638

Purchase accounting depreciation and amortization

753

1,028

Postretirement benefit plan settlement gain

(1,285)

Litigation settlement

26

1,946

(Loss) income from operations, as adjusted

$ (1,499)

$ 6,448

$ 17,322

$ 23,218

Net (loss) income, as reported

$ (8,641)